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CHAPTER I 
 
INTRODUCTION 
 
Poor water solubility, toxicity, off-target effects, and lack of sustained release formulas 
are the most significant barriers limiting drug development and drug delivery.
1,
 
2,
 
3,
 
4
 Not 
surprisingly, many promising chemotherapeutics, antibiotics, and peptide therapeutics have 
failed clinically due to these issues. As a consequence, expensive and time-consuming medicinal 
chemistry approaches are used to increase solubility of these drugs but often at the expense of 
drug efficacy. Alternatively, many drugs are shelved, and efforts are used to develop new 
therapies. A superior, more time- and cost-effective approach is to develop and apply 
nanoformulations of these promising drugs. This is accomplished using biodegradable 
nanoparticles or hydrogels that can aid in drug solubilization, have the ability to target the 
therapeutic cargo to a specific site in the body, and allow for a sustained release of the drug at a 
defined rate. 
While nanotechnology continues to make significant advances in the diagnosis, 
prevention, and treatment of various diseases
5,
 
6
, significant time and money are expended every 
year to develop new therapeutics, and the majority fail to enter the market due to solubility. 
Developed drug delivery vehicles possess the ability to encapsulate or incorporate therapeutic 
cargo within their networks. In the case of hydrophobic drugs, the drugs are confined to the 
nanoscale which decreases crystallinity thereby increasing water solubility. In this way, 
hydrophobic drugs can potentially overcome their solubility issues through encapsulation into a 
platform drug delivery vehicle.  
2 
 
Biodegradable polymers are widely investigated for their potential as building blocks for 
advanced drug delivery vehicles. Polyesters remain the most studied class of polymer due to its 
low immunogenicity, low toxicity, biocompatibility, and hydrolytically cleavable ester bonds.
7
 
Recently, polycarbonates have garnered significant attention as drug delivery materials due to 
their low toxicity, amorphous characteristic at room and body temperature, and very slow 
degradation rates.
8,
 
9,
 
10
 The ability to utilize these polymers as building blocks for 
supramolecular drug delivery vehicles is dependent on the ability to consistently synthesize well-
defined polymer precursors. Therefore, methods to synthesize functionalized polymers in a well-
controlled manner are paramount for the advancement of polymeric drug delivery applications.  
Organocatalysts for ring opening polymerization of ester and carbonate monomers are 
well studied and have received much attention due to their metal-free conditions. This class of 
catalyst has proven useful for the successful formation of well-defined, functionalized polyesters 
and polycarbonates which can be used to synthesize supramolecular structures such as hydrogels 
and nanoparticles.
11, 12
 However, most organocatalysts are sensitive to moisture and require very 
pure monomers thus requiring the use of a glovebox and extensive purification steps.
13, 14
 
Because of this, time and materials become limiting factors for the synthesis of polymer 
precursors. Alternatively, metal catalysts for ring opening polymerizations offer significantly less 
strict reaction conditions. Tin octanoate is one of the most popular of the metal catalysts due to 
its low toxicity and effectiveness for synthesizing various types of polymers.
15,
 
16,
 
17
 However, 
high temperatures, long polymerization times, and high dispersities limit the applicability of this 
catalyst for well-defined, functionalized polymer precursors. Tin triflate, on the other hand, is not 
as well studied for the polymerization of functionalized polyesters and polycarbonates but was 
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determined to be an effective catalyst to yield predictable polymers with low dispersities without 
excessive heat or reaction times.  
Of the many obstacles that limit drug effectiveness and applicability, solubility is the 
most essential factor. Poor water-solubility of drugs is a significant limitation for many 
promising therapeutics causing low bioavailability, inability to cross membranes, and poor 
efficacy. Drugs in classes II and IV of the BCS classification system are characterized by poor 
solubility. For example, paclitaxel is a powerful chemotherapeutic classified as a class IV drug 
meaning poor solubility as well as poor permeability.
18
 Numerous approaches have been utilized 
to improve the bioavailability and effectiveness of paclitaxel such as attaching to albumin 
(Abraxane) and administering with Cremophor oil (Taxol). However, toxic side effects and 
inability for tumor targeting impose significant limitations.
19
 Alternatively, drug delivery 
approaches have been developed to improve the solubility and efficacy of paclitaxel. For 
example, micelles are capable of loading hydrophobic drugs, but typically result in quick and 
rapid drug release and accumulation in the liver.
20,
 
21,
 
22  Polymeric nanoparticles are heavily 
investigated for the delivery of hydrophobic drugs such as paclitaxel. However, many lack 
necessary characteristics such as biodegradability, controlled release, and targeting 
capabilities.
23,
 
24,
 
25
 Therefore, a need still remains for the development of a platform drug 
delivery vehicle capable of tunable and controlled drug release as well as targeting capabilities. 
An ideal vehicle would have the following characteristics: biodegradable and amorphous 
structures that can be scaled from 20 nm to 800 nm, have the ability to allow predictable and 
controlled linear drug release kinetics, achieve efficient encapsulation of hydrophobic drugs that 
would decrease drug crystallinity and increase solubility, possess functional groups capable of 
orthogonal chemistries for the attachment of imaging dyes and targeting moieties, and can be 
4 
 
combined with other delivery methods for combined drug delivery therapies. Collectively, the 
ability to incorporate these unique properties into a single nanoparticle drug delivery system 
allows for optimization of many drug therapies including cancer, diabetes, and bone healing. The 
development of this technology allows for the advanced progress of the treatments of these 
diseases by addressing the critical clinical barrier of drug solubility, sustained release formulas, 
and targeting.  
 Of all therapeutic routes, oral delivery is by far the most convenient but also perhaps the 
most difficult and complex. Therapeutics must be able to survive the acid and enzyme rich 
conditions of the stomach and gastrointestinal tract, have favorable uptake capability in the 
intestines, and pass through the metabolic liver before entering systemic blood flow.  However, 
overcoming any one of these barriers can significantly increase the oral bioavailability of a drug. 
Solubility remains a major issue since solubilization is typically required for intestinal 
transport.
26
 Although nanoparticles can help solubilize hydrophobic drugs, polyester vehicles are 
believed to degrade rapidly in the stomach due to acid-catalyzed hydrolysis. Also, nanoparticle 
size plays a significant role in its ability to be taken up intestinally.
27
 Lipid-based particles have 
shown great ability to encapsulate drugs and enhance lipophilicity of the drug for better intestinal 
uptake, but the lipid makeup of the vehicle leads to secretion of lipase enzyme which breaks 
down the vehicle in the intestines.
28
 Thus, there remains a need for an advanced drug delivery 
vehicle that will not significantly degrade or release therapeutic cargo in the acidic stomach and 
also possess an ideal size that can be taken up by the intestines. The advancement of such a 
vehicle could significantly improve the oral bioavailability of drugs with low solubility and low 
intestinal uptake. 
5 
 
Combination therapies offer intriguing approaches to treat complex diseases in which 
multiple signaling pathways are affected. Since drug delivery vehicles are often designed for the 
delivery of a single class of therapeutic, the delivery of two different classes of therapeutics such 
as a small molecule and peptide imposes a major challenge. For example, bone morphogenetic 
protein 2 (BMP2) has become a popular therapeutic due to its ability to improve the bone healing 
process for numerous orthopedic applications.
29,
 
30,
 
31
However, the delivery of peptide and 
protein therapeutics are particularly challenging since they are often cleared or degraded within 
hours upon administration. Larger biologically active cargo is also more difficult to incorporate 
into nano and macro delivery devices. Methods to improve protein therapeutic half-lives 
primarily rely on pegylation strategies that often lead to decreased efficacy.
32
 However, a non-
covalent incorporation into a PEG-like environment would mediate a slower 
degradation/clearance rate and not affect therapeutic efficacy which could significantly improve 
the use of protein and peptide therapeutics. Therefore, novel delivery systems that are capable of 
entrapping and delivering various combinations of drugs are necessary and would provide a 
major impact on the treatment of critical diseases. For example, skeletal disorders associated 
with neurofibromatosis 1 (NF1), which can result in reduced bone mineral density, long bone 
dysplasia, and morbidity associated with focal bony lesions, remain difficult to treat despite 
advances in medicine and technology, and combination therapies may be required to treat these 
disorders.
33
 Noninvasive approaches are limited as most options include surgery, amputation, or 
open fracture treatments. Ideally, patients could be treated through a single, noninvasive 
injection. Since solubility remains a major hurdle for most pharmacologically active drugs and 
sustained release formulas are desired to circumvent frequent dosing, a novel formulation that 
allows the sustained release of a protein and small molecule drug could prove useful.  
6 
 
A multi-functional nanoparticle that is capable of both imaging dye and targeting ligand 
attachment would allow not only the potential to act as a way to image specific cells, but also 
allow for the restricted, targeted delivery of drugs to these cells. For example, two of the primary 
goals of diabetes research are the development of technology that allows for the tracking of beta 
cells in the pancreatic islets and technology to deliver therapeutic agents specifically to 
pancreatic islet cells. Currently, there are a number of interventional strategies under 
development that seek to promote beta cell regeneration, halt or slow beta cell apoptosis, and 
protect islets from autoimmune attack. However, these approaches often suffer from undesirable 
off target effects on other cell types that share common pathways or targets with the pancreatic 
islet. The ability to specifically target and image these cells remains a major goal for scientists 
and doctors, and this ability would allow the potential delivery of therapeutic agents such as 
small molecule drugs or even siRNA specifically to these cells for the improved treatment of 
patients.  
Hydrogels remain an attractive biomaterial for the application of implants and sustained 
drug release formulas due to their biocompatibility, mechanical properties, and simple synthetic 
methods. One of the hallmarks of traditional hydrogels is the ability to swell several times their 
own volume with water, but because of this, drug release through diffusion is often faster than 
desired. Also, polymers such as acrylates are nondegradable and therefore must be surgically 
removed after implantation. Alternatively, degradable, more hydrophobic polymers such as 
polycarbonates could be used to form hydrogels that could allow less water swelling and 
potentially a slower release of drug over time. Therefore, an appropriate balance of hydrophobic 
and hydrophilic components within a hydrogel network must be achieved in order to improve the 
limitation of rapid drug release typically seen in traditional hydrogel systems. The ability to 
7 
 
easily tune the swelling and degradation of a gel would allow for a customizable design that 
could potentially meet any sustained drug release application.  
 
Dissertation Overview 
 Nanonetwork strategies have been developed to overcome the issues of drug solubility, 
toxicity, targeting, sustained release, and combination treatments. Amine-epoxide and thiolene-
click intermolecular crosslinking chemistries were used to synthesize supramolecular structures 
from functionalized polycarbonates and polyesters. Although organocatalysts were initially 
utilized to synthesize polycarbonates, more practical polymerization conditions were developed 
utilizing tin triflate to afford well-defined, functionalized polycarbonates and polyesters.  
 Using epoxide-functionalized polyesters and 2,2’-ethylenedioxy-bis(ethylamine), 
polyesters underwent an intermolecular crosslinking reaction to form 3-dimensional, nano-sized 
architectures containing hydrophobic components from the polyester and hydrophilic 
components from the ethylene-oxide crosslinker. Particles with different crosslinking densities 
were synthesized and were used to encapsulate and nanosolubilize small molecule drugs such as 
paclitaxel. The crosslinking density has a critical effect on drug release and can be tailored to 
release a drug at a defined rate. The ability to withhold the majority of the therapeutic cargo after 
several hours in simulated gastric fluid indicates the possibility of these polyester nanosponges to 
act as oral drug delivery vehicles.  
 In order to treat complex bone disorders by acting on two different signaling pathways, 
polyester nanoparticles containing a water-insoluble MEK inhibitor was formulated with a 
polyglycidol matrix containing a protein growth factor, bone morphogenetic protein 2 (BMP2). 
This combined, injectable formulation allowed for the sustained release of the two different 
8 
 
classes of therapeutics simultaneously, and its usefulness and efficacy were investigated for bone 
healing applications in vivo. 
 Pendant functional groups on the nanoparticle surface such as allyls and amines were 
utilized for post-modification reactions, including thiolene-click reactions to attach targeting 
moieties. For applications that utilized targeting peptides, orthogonal approaches were developed 
in order to successfully attach both the targeting peptide and an imaging dye without side 
reactions.  
 The same concept of using intermolecular crosslinking reactions to form nanoparticles 
was used to form hydrogels under concentrated conditions. Using allyl-functionalized 
polycarbonates and PEG-dithiol crosslinkers, polycarbonates underwent intermolecular 
crosslinking reactions via thiolene-click to form insoluble hydrogel materials. Hydrogels were 
formed using crosslinkers of different sizes as well as incorporating hydrophilic components 
(polyglycidol) in the hydrogel network. Gels could also be formed in the presence of drugs such 
as paclitaxel, thereby entrapping the drug within the gel network. Crosslinker size and presence 
of polyglycidol both had significant impacts on mechanical properties such as swelling and also 
significant effects on drug release rates.  
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CHAPTER II 
 
POLYCARBONATE NANOSPONGES SYNTHESIZED FROM ORGANOCATALYZED 
CARBONATE COPOLYMERS 
 
Introduction 
The synthesis and engineering of biomaterials for applications in tissue engineering, 
wound healing, and drug delivery are the driving forces in the development of defined and 
functionalized materials. While the preparation of polyester and polycarbonate based particles 
has been mainly driven by precipitation processes, chemically driven nanoparticle formation has 
given the opportunity to control sizes and the architectural nature of the particles. 
Intramolecular1, 2 and inter chain-crosslinking processes3, 4 have been developed into suitable 
methods to form versatile supramolecular structures. In particular, intermolecular chain cross-
linking of side-chain functional polyesters derived by ring-opening polymerization of substituted 
δ-valerolactone monomers5, 6, 7 affords controlled nanoparticle sizes that can be varied via the 
percentiles of side-chain functionalities into the linear polyester precursor.  Furthermore, the 
morphology and size can be controlled with the amount of difunctionalized cross-linking units 
which react with the side-chain functionality of the polymer. With this, functionalized particles 
that are further post-modified with targeting units, and upon drug encapsulation, can be tested for 
their biological response as drug delivery systems.8, 9 A wide range of degradable polymers have 
been investigated for in vivo applications.10, 11, 12, 13 Polyesters are most commonly studied due to 
their degradability and non-toxic degradation products; however, the introduction of side-chain 
14 
 
functional groups is typically challenging and can limit their applicability in advanced 
applications.11, 14  
Polycarbonates prepared by the ring-opening polymerization (ROP) of 6-membered 
cyclic monomers have been widely explored for these applications, and organocatalysis has 
provided efficient routes to realize a range of functionalized polymer structures.15, 16, 17 Recently, 
a range of functional monomers and polymers have been explored from simple precursors giving 
access to unprecedented levels of functional group incorporation.18, 19, 20 Importantly, 
polycarbonate materials display slower degradation profiles with less toxic byproducts than 
polyesters thus making them ideal candidates as one of the building blocks for advanced 
nanomaterials.14 Herein, we demonstrate that synthesized allyl-functional aliphatic 
polycarbonates can be transformed into epoxide-functional aliphatic polycarbonates and can be 
employed in the intermolecular chain crosslinking process for the synthesis of polycarbonate 
nanosponges. 
 
Results and Discussion 
Advanced organocatalytic synthesis methods were employed to prepare linear 
polycarbonates with control over functional group incorporation and molecular weight. The 
incorporation of the allyl group allows for immediate nanosponge formation via thiolene click 
reactions or further modification through full conversion of the allyl to an epoxide.  Pendant allyl 
or epoxide groups served as reaction partners in thiolene click or epoxide-amine reactions with 
ethylene oxide-containing crosslinkers to form a panel of six novel polycarbonate nanosponges 
with crosslinking densities containing 5, 10, or 20% via an intermolecular chain crosslinking 
approach. 
15 
 
Synthesis of ethyl and allyl functionalized carbonate monomers 
 
 
  
 The ability to synthesize cyclic monomers with various functional groups in a cost-
effective and high yielding manner is paramount for the production and application of advanced 
polymer systems. To achieve this, numerous approaches have focused on the use of cyclic 
carbonate monomers derived from 1,3-diols. For example, a simple, two-step synthesis has been 
utilized to synthesize cyclic carbonate monomers with a wide variety of functional groups.
18
 In 
this approach, 2,2-bis(hydroxymethyl)-propionic acid undergoes both ring-closing and a 
pentafluorophenyl attachment at the carboxylic acid in a single step. In the second step, 
nucleophilic substitution is utilized to attach various functionalities since pentafluorophenyl is an 
excellent leaving group (Figure II-1 pathway A). This pathway is advantageous since it requires 
only two steps and the reactive intermediate after the first step can be utilized to form various 
other functionalized monomers in the second step such as bromo, chloro, and alkyne 
 
Figure II-1. Two reported synthetic pathways to form allyl and ethyl functionalized cyclic 
carbonate monomers. 
Pathway A
Pathway B
R = 
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functionalities. However, this pathway is also quite expensive and yields are generally low (less 
than 50%). 
 An alternative two-step synthesis pathway can be used to form the same functionalized 
monomers but at significantly lower costs and higher yields. In this approach, 2,2-
bis(hydroxymethyl)-propionic acid first undergoes esterification followed by ring-closing in the 
second step (Figure II-1 pathway B). For example, 2,2-bis(hydroxymethyl)-propionic acid can 
react with ethanol using heat and Amberlyst-15 resin to form ethyl 3-hydroxy-2-
(hydroxymethyl)-2-methylpropanoate (88% yield) followed by a ring closure reaction using 
triethylamine and ethyl chloroformate (71% yield). Although each functionalized monomer must 
undergo its own individual synthetic route as opposed to using a single reactive intermediate 
seen in pathway A, the yields are significantly higher while keeping costs significantly lower. 
 
Synthesis of functionalized, linear polycarbonates 
Extension of the organocatalytic methods for ROP of 5-methyl-5-allyloxycarbonyl-1,3-
dioxane-2-one (MAC) was undertaken to prepare a series of novel copolymers with 5-methyl-5-
ethyloxycarbonyl-1,3-dioxane-2-one (MEC) to provide a series of three copolymers (Figure II-3) 
initiated from benzyl alcohol using the (−)-sparteine/thiourea catalyst system with controlled 
functional group densities.
21
 The observed copolymers showed good control in molecular weight 
but slightly broad dispersities that are a consequence of high molecular weight tailing of the 
polymer distributions at high conversions (Figure II-3). It was decided that these polymers were 
suitable to test the ability and performance in nanoparticle formation since the incorporation of 
the MAC monomer, which contains the allyl functionality, was consistent with the monomer 
feed ratios as confirmed by 
1
H NMR spectroscopy. As an alternative methodology, particle 
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formation using epoxide-amine crosslinking chemistry was also employed. As previously 
demonstrated by Storey and coworkers
22
, the oxidation of allyl-functional polycarbonates with 
meta-chloroperoxybenzoic acid (mCPBA) results in the formation of the epoxide-functional 
polymers. This provides an alternative group that is very valuable to the synthesis of 
nanoparticles and functionalization reactions for surface labeling.  
 
 
 
The MAC-containing copolymers were fully epoxidized (100% conversion as indicated by 
1
H 
NMR analysis) by treatment with 1.2 equivalents mCPBA in CH2Cl2 to form the suitable linear 
precursor. The disappearance of the characteristic alkene resonances in the range δ = 5.9−5.3 
ppm was observed with the appearance of resonances that are clearly attributable to the 
formation of epoxide-functional polymers at δ = 3.19, 2.82, and 2.63 ppm. Other resonances in 
the 
1
H NMR spectra of the polymers did not change and the same chain length was determined 
by end group analysis. 
 
Figure II-2. Synthesis of allyl-functionalized polycarbonate copolymers and their subsequent 
conversion to epoxide groups. 
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Polycarbonate nanosponge formation via thiolene-click chemistry 
The ability of the copolymers to form nanoparticles was investigated initially via the 
previously developed thiolene-click chemistry. To investigate polycarbonate-based nanosponge 
formation, a panel of three copolymers containing 5, 10, and 20% MAC was planned to react 
with the dithiolethyleneoxide crosslinker. We sought to keep the equivalents of the 
difunctionalized crosslinker constant to investigate the control of size dimensions with a 
variation of the cross-linking density in the linear precursor; therefore, all reactions were 
completed using 4 equivalents of respective difuctionalized crosslinker (8 equivalents 
thiol/allyl). Transmission electron microscopy (TEM) and dynamic light scattering (DLS) 
analysis demonstrated that polycarbonate-based nanosponges could be successfully prepared 
employing intermolecular crosslinking reactions. The increasing amount of allyl functionality in 
 
Figure II-3. Molecular weight and PDI were determined using GPC calibrated with 
poly(styrene) standards in chloroform. Conversion and molecular weight were determined by 
NMR. The legend for the GPC traces refers to the percentile of MAC monomer in the 
copolymer. 
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the polymer backbone led to larger particles for the series as displayed by the number-average 
hydrodynamic diameters, Dh = 220 nm for the 20% crosslinker-containing particles, in contrast 
to smaller particle sizes of Dh = 150 nm for the particles prepared with 5% MAC comonomer 
incorporated. The DLS data shown in Figure II-5 in logarithmic scale underlined the chemically 
driven nanoparticle formation via the intermolecular chain collapse process using the cross-
linking density to control the nanoparticle formation. In comparison to thiolene-click reactions 
with analogous polyester linear polymers
7
, the polycarbonate-derived particles are smaller than 
expected, attributed to a lower degree of polymerization (DP) of the polycarbonate copolymers  
 
 
 
Figure II-4. Intermolecular chain crosslinking with either amine-epoxide or thiolene-click 
chemistries to form nanosponges. 
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(DP = 20) than those reported from the polyester polymers and its analogs (DP = 50). 
Regardless, particles of increasing diameter could be synthesized between 150 nm and 220 nm 
by increasing the percentage of allyl functionality between the range of 5% and 20% present in 
the polycarbonate precursor. 
 
Polycarbonate nanosponge formation via amine-epoxide chemistry 
 
 
 
Reaction of the panel of functionalized copolymers containing 5, 10, and 20% epoxide 
pendant functional groups with 4 equivalents diaminoethyleneoxide (8 equivalents 
amine/epoxide) was performed to crosslink the polymers. Analysis of the resultant nanosponges, 
again by TEM and DLS, demonstrated that particle size was dependent on crosslinking density 
 
Figure II-5. Top row: DLS analysis data for both particle series derived from the two panels 
of copolymer precursors with amine-epoxide and the thiolene-click reactions. TEM images 
of two representative polycarbonate nanosponges: left, 5% amine−epoxide; right, 5% 
thiolene-click. 
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as can be seen for sizes of Dh = 230 nm for the particles with 20% cross-linking in contrast to Dh 
= 160 nm for particles prepared from the lowest crosslinking density available in the study 
(Figure II-5). In comparison to analogous polyester materials, the particle sizes are again smaller, 
attributed to the lower degree of polymerization in contrast to the previously investigated 
polyester materials. Notably, however, the different preparation methods have resulted in 
comparably sized particles, demonstrating the versatile synthesis of these nanomaterials. 
Therefore, polycarbonate nanoparticles can be synthesized using either thiolene-click or amine-
epoxide to achieve similar sized particles. 
 
Conclusion 
In summary, for the first time, we have demonstrated the formation of a range of novel 
functionalized polycarbonate nanoparticles using two different chemistries with the established 
intermolecular cross-linking process. We have prepared functionalized polycarbonate 
copolymers of 5-methyl-5-allyl-oxycarbonyl-1,3-dioxan-2-one (MAC) and 5-methyl-5-
ethyloxycarbonyl-1,3-dioxane-2-one (MEC) via organocatalytic synthesis under mild conditions 
using a thiourea and (−)-sparteine catalyst system. The pendant allyl groups were utilized as 
cross-linking partners in thiolene click reactions forming nanosponges in the sizes of 150−220 
nm depending on the cross-linking density of the linear precursor with 5, 10, and 20% of pendant 
allyl groups incorporated. The oxidation of the allyl groups in the copolymers to epoxides was 
successful, and the following crosslinking reaction with diamines enabled the synthesis of the 
nanosponge particles in size ranges of 160−230 nm using the alternative epoxide-amine 
chemistry. The ability to synthesize particles of similar size from two different chemistries 
demonstrates the versatility of this technology to be used for advanced materials. These studies 
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demonstrate the potential to form a basis for complex degradable nanoparticle syntheses for 
controlled release applications. 
 
Experimental 
Materials  
CDCl3 and (-)-sparteine were dried over CaH2, distilled, degassed and stored under inert 
atmosphere. Benzyl alcohol was dried and stored over 4 Å molecular sieves under inert 
atmosphere. Methylene chloride was purified over an Innovative Technology SPS alumina 
solvent column and degassed before use. 5-Methyl-5-allyloxycarbonyl-1,3-dioxan-2-one (MAC) 
and 5-methyl-2-oxo-1,3-dioxane-5-carboxylate (MEC) were synthesized as reported 
previously
23
, 
24
 and recrystallized several times before use and dried over CaH2 in dry THF at 
50-60 °C. 1-(3,5-Bis(trifluoromethyl)phenyl)-3-cyclohexylthiourea was synthesized as 
previously reported
25
 then dried over calcium hydride in dry tetrahydrofuran and recrystallized 
from dry methylene chloride. Silica Gel (pore size = 40 Å) was obtained from Fisher Scientific 
and used as received. All other solvents and chemicals were obtained from Sigma Aldrich or 
Fisher Scientific and used as received.  
 
Characterization 
Polymerizations were performed under inert atmosphere in a glovebox. 
1
H NMR and 
13
C NMR 
spectra at Warwick were recorded on a Bruker DPX-300, DPX-400, DRX-500 or AV II-700 
spectrometer at 293K. Chemical shifts are reported as δ in parts per million (ppm) and referenced 
to the residual solvent signal (CDCl3: 
1
H, δ = 7.26 ppm; 13C, δ = 77.16 ppm; (CD3)2SO: 1H, δ = 
2.50; 13C, δ = 39.52). Gel-permeation chromatography (GPC) was used to determine the 
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molecular weights and polydispersities of the synthesized polymers. GPC in THF was conducted 
on a system composed of a Varian 390-LC-Multi detector suite fitted with differential refractive 
index (DRI), light scattering (LS), and ultraviolet (UV) detectors equipped with a guard column 
(Varian Polymer Laboratories PLGel 5 μM, 50 × 7.5 mm) and two mixed D columns (Varian 
Polymer Laboratories PLGel 5 μM, 300 × 7.5 mm). The mobile phase was either tetrahydrofuran 
eluent or tetrahydrofuran with 5% triethylamine eluent at a flow rate of 1.0 mL/min, and samples 
were calibrated against Varian Polymer Laboratories Easi-Vials linear poly(styrene) standards 
(162-3.7 × 105 g mol
-1
) using Cirrus v3. The dymamic light scattering (DLS) measurements 
were performed by Mr. Jerry Cabiness from Nanosight Inc. and were measured in CH2Cl2 as 
solvent. Samples for transmission electron microscopy (TEM) imaging were prepared by 
dissolving 0.5 mg nanoparticles in a solution of 1 mL isopropanol, 0.3 mL acetonitrile and 0.2 
mL toluene. The samples were sonicated for 5 min and stained with 3 drops of 3% 
phosphotungstic acid. The carbon grids were prepared by slowly dipping an Ultrathin Carbon 
Type-A 400 Mesh Copper Grid (Ted Pella, Inc., Redding, CA) into the particle solution three 
times and air drying the grid at room temperature. A Philips CM20T transmission electron 
microscope operating at 200 kV in bright-field mode was used to obtain TEM micrographs of the 
polymeric nanoparticles.  
 
General procedure for Ring–Opening Polymerization  
Polymerizations were completed in glovebox. A solution of ethyl 5-methyl-2-oxo-1,3-dioxane-5-
carboxylate (397 mg, 2.112 mmol) and allyl 5-methyl-2-oxo-1,3-dioxane-5-carboxylate (106 mg, 
0.528 mmol) in CH2Cl2 (0.84 mL) was added to a stirred solution of 1-(3,5-
bis(trifluoromethyl)phenyl)-3-cyclohexylthiourea (97.8 mg, 0.264 mmol), benzyl alcohol (13.7 
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μL, 0.132 mmol) and sparteine (30.3 μL, 0.132 mmol) in CH2Cl2 (0.84 mL). After the allotted 
period of time, the reaction was twice precipitated from CH2Cl2 into hexanes and dried under 
reduced pressure. Residual catalyst impurities were removed by column chromatography on 
silica (80% hexanes, 20% ethyl acetate). Purified polymer was dried under reduced pressure. 
1
H 
NMR (400MHz, CDCl3/TMS, ppm) δ: 7.37 (m, OBn-ArH), 5.9 (m, CHvinyl), 5.3 (m, CH2-
vinyl), 5.15 (s, OBn-CH2), 4.64 (m, OCH2CHCH2), 4.40-4.18 (m, MAC & MEC, OC(O)OCH2), 
1.30-1.22 (m, MAC, CH3; MEC, OCH2CH3)  
 
General procedure for oxidation of copolymers  
3-Chloroperoxybenzoic acid (30.4 mg, 0.176 mmol) was added to a stirred solution of 
poly(MEC, MAC) (0.200 g, 0.214 mmol) in CH2Cl2 (3.7 mL). The mixture stirred for 48 hours 
at room temperature. Residual 3-chloroperoxybenzoic acid was removed by dialysis against 
dichloromethane using Spectra/Por Dialysis Membrane (MWCO = 2,000) to yield pure polymer 
(0.180 g). 
1
H NMR (400MHz, CDCl3/TMS, ppm) δ: The significant change is the disappearance 
of the allylic protons at 5.9 and 5.3 ppm and the emergence of small broad peaks at 3.19, 2.82, 
and 2.63 ppm due to formation of the epoxide ring.  
 
Poly(5% MAC, 95% MEC) nanoparticle formation using thiolene crosslinking  
3,6-dioxa-1,8-octane-dithiol (18.4 μL, 0.113 mmol) was added to a solution of poly(5% MAC, 
95% MEC) (100 mg, Mn = 5.0 kDa, PDI = 1.56) in CH2Cl2 (8.7 mL). The reaction mixture 
refluxed for 12 hours at 45 °C. Residual crosslinker was removed by dialyzing with SnakeSkin 
Pleated Dialysis Tubing (MWCO = 10,000) against CH2Cl2 to yield particles (96 mg). 
1
H NMR 
(400MHz, CDCl3/TMS, ppm) δ: The significant change is the disappearance of the allylic 
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protons at 5.9 and 5.3 ppm and the emergence of peaks at 3.64 ppm due to the methylene protons 
adjacent to the oxygens in the crosslinker and 2.73-2.68 ppm due to methylene protons adjacent 
to the sulfide functionality.  
 
Poly(10% MAC, 90% MEC) nanoparticle formation using thiolene crosslinking  
3,6-dioxa-1,8-octane-dithiol (34.3 μL, 0.209 mmol) was added to a solution of poly(10% MAC, 
90% MEC) (100 mg, Mn = 5.3 kDa, PDI = 1.25) dissolved in CH2Cl2 (16.2 mL). The reaction 
mixture refluxed at 12 hours at 45 °C. Residual dithiol was removed by dialyzing with 
SnakeSkin Pleated Dialysis Tubing (MWCO = 10,000) against CH2Cl2 to yield particles (90 
mg). 
1
H NMR (400MHz, CDCl3/TMS, ppm) δ: The significant change is the disappearance of 
the allylic protons at 5.9 and 5.3 ppm and the emergence of peaks at 3.64 ppm due to the 
methylene protons adjacent to the oxygens in the crosslinker and 2.73-2.68 ppm due to 
methylene protons adjacent to the sulfide functionality.  
 
Poly(20% MAC, 80% MEC) nanoparticle formation using thiolene crosslinking  
3,6-dioxa-1,8-octane-dithiol (70.1 μL, 0.428 mmol) was added to a solution of poly(20% MAC, 
80% MEC) (100 mg, Mn = 6.4 kDa, PDI = 1.39) in CH2Cl2 (33.0 mL). The reaction mixture 
refluxed at 12 hours at 45 °C. Residual dithiol was removed by dialyzing with SnakeSkin Pleated 
Dialysis Tubing (MWCO = 10,000) against CH2Cl2 to yield particles (90 mg). 
1
H NMR 
(400MHz, CDCl3/TMS, ppm) δ: The significant change is the disappearance of the allylic 
protons at 5.8 and 5.3 ppm and the emergence of peaks at 3.64 ppm due to the methylene protons 
adjacent to the oxygens in the crosslinker and 2.73-2.68 ppm due to methylene protons adjacent 
to the sulfide functionality.  
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Poly(5% MTC-epox, 95% MEC) nanoparticle formation using epoxide-amine crosslinking 
 
2,2’-ethylenedioxy-bis(ethylamine) (22.9 μL, 0.157 mmol) was added to a solution of poly(5% 
MTC-epox, 95% MEC) (140 mg, Mn = 5.0 kDa, PDI = 1.56) dissolved in CH2Cl2 (12.1 mL). 
The reaction mixture refluxed at 12 hours at 45 °C. Residual bisamine was removed by dialyzing 
with Snakeskin Pleated Dialysis Tubing (MWCO = 10,000) against CH2Cl2 to yield particles 
(130 mg). 1H NMR (400MHz, CDCl3/TMS, ppm) δ: The significant change is the disappearance 
of the epoxide ring protons at 3.19, 2.82, and 2.63 ppm and the emergence of peaks at 3.62-3.56 
ppm due to the methylene protons adjacent to the oxygens in the crosslinker and 3.36 ppm 
corresponding to the protons neighboring the secondary amine of the PEG linker after 
crosslinking.  
 
Poly(10% MTC-epox, 90% MEC) nanoparticle formation using epoxide-amine 
crosslinking 
 
2,2’-ethylenedioxy-bis(ethylamine) (27.0 μL, 0.187 mmol) was added to a solution of poly(10% 
MTC-epox, 90% MEC) (90 mg, Mn = 5.3 kDa, PDI = 1.25) dissolved in CH2Cl2 (14.4 mL). The 
reaction mixture refluxed at 12 hours at 45 °C. Residual bisamine was removed by dialyzing 
with Snakeskin Pleated Dialysis Tubing (MWCO = 10,000) against CH2Cl2 to yield particles (71 
mg). 
1
H NMR (400MHz, CDCl3/TMS, ppm) δ: The significant change is the disappearance of 
the epoxide ring protons at 3.19, 2.82, and 2.63 ppm and the emergence of peaks at 3.62-3.56 
ppm due to the methylene protons adjacent to the oxygens in the crosslinker and 3.36 ppm 
corresponding to the protons neighboring the secondary amine of the PEG linker after 
crosslinking.  
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Poly(20% MTC-epox, 80% MEC) nanoparticle formation using epoxide-amine 
crosslinking 
 
2,2’-ethylenedioxy-bis(ethylamine) (61.8 μL, 0.420 mmol) was added to a solution of poly(20% 
MTC-epox, 80% MEC) (100 mg, Mn = 6.6 kDa, PDI = 1.39) dissolved in CH2Cl2 (32.5 mL). 
The reaction mixture refluxed at 12 hours at 45 °C. Residual bisamine was removed by dialyzing 
with Snakeskin Pleated Dialysis Tubing (MWCO = 10,000) against CH2Cl2 to yield particles (74 
mg). 
1
H NMR (400MHz, CDCl3/TMS, ppm) δ: The significant change is the disappearance of 
the epoxide ring protons at 3.19, 2.82, and 2.63 ppm and the emergence of peaks at 3.62-3.56 
ppm due to the methylene protons adjacent to the oxygens in the crosslinker and 3.36 ppm 
corresponding to the protons neighboring the secondary amine of the PEG linker after 
crosslinking.  
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CHAPTER III 
 
TIN TRIFLATE CATALYZED RING-OPENING POLYMERIZATION OF 
FUNCTIONALIZED LACTONES AND CARBONATES 
 
Introduction 
 Functional polyester and polycarbonate materials are two of the most important classes of 
degradable polymers used in biomedical applications.
1,
 
2,
 
3,
 
4
 To further advance the field and 
design specialized delivery materials, a practical and well-controlled synthesis of functionalized 
linear polyesters and polycarbonates is paramount. These building blocks enable the preparation 
of more complex systems such as nanoparticles for drug release
5
 with the goal to overcome 
limitations of traditional polyester materials such as crystallinity. These building blocks are also 
valuable for the development of other advanced biomedical materials such as hydrogels.
6
 Here, 
the integrated functionalities along the polymer backbone allow reactions with hydrophilic 
crosslinking units to obtain nanoparticles with decreased crystallinity
7
 and tailored release rates 
as observed in developed nanosponges.
8
   
 Sn(Oct)2 has been the most applied metal catalyst to prepare polyester homo and 
copolymers in ring-opening polymerization (ROP) techniques.
5, 9
 Numerous approaches have 
also demonstrated its versatility through the incorporation of functional groups such as allyls, 
ketones, and propargyls and have been utilized in the formation of specialized nanomaterials 
such as drug release particles
10
 and layered coatings
11
. Nevertheless, reaction temperatures of 
over 100 °C and high polydispersities (PDIs) have been reported, and polymers require dialysis 
to achieve narrower polydispersities. However, there are only a few reports investigating ring-
opening polymerization procedures for the preparation of polyester homo and copolymers with 
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Sn(OTf)2 as catalyst. Sn(OTf)2 has not been intensively investigated yet due to its reported high 
reactivity and formation of bimodal polymers that can only be purified by column 
chromatography.
12
 Moreover, the polymerization of functionalized cyclic carbonate monomers 
derived of the 5-methyl-2-oxo-1,3-dioxane-5-carboxylate family have not been studied with this 
particular catalyst.
13
 Previous reports have focused on aluminum, alkaline earth-based catalysts, 
rare earth metal-based catalysts, and transition metal-based catalytic systems, but many of these 
systems yielded polymers with typical PDI’s of 1.30 and 2.50.14, 15, 16   
 The development of organic catalysts has led to polyesters and polycarbonates with 
narrow polydispersities and good incorporation of functional groups.
17,
 
18,
 
19
 However, the 
primary disadvantage of organic catalysts is the strict inert atmosphere conditions that are 
required to prepare well-defined polymers. This leads to extensive preparation times in addition 
to the actual synthesis and typically must be completed inside a glovebox. Although 
organocatalysts are preferred for recyclable plastics and microelectronics, polyester materials 
prepared via metal catalysis are widely used for biomedical applications.
20
 
 Therefore, we sought to revisit metal-catalyzed polymerization techniques but investigate 
more active catalysts that work at room temperature and produce well defined polyesters and 
polycarbonates.
21,
 
12
 Methods were developed by investigating ideal temperatures, reaction 
times, reaction conditions, catalyst and monomer concentrations, and initiator selection. In this 
work, we present the controlled living ring-opening polymerization of functionalized polyesters 
and polycarbonates with Sn(OTf)2 that does not require the use of a glovebox and gives, in 
simple and practical approaches, well-defined polyesters and polycarbonates with narrow 
polydispersities.  
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Results and Discussion 
We report the synthesis of functionalized polycarbonates and polyesters employing 
stannous (II) trifluoromethane sulfonate [Sn(OTf)2] in homo and copolymerizations with 
monomers of the valerolactone family such as valerolactone and δ -allyl-valerolactone using 
ring-opening polymerization (ROP) techniques and cyclic carbonate monomers such as 5-
methyl-5-allyloxycarbonyl-1,3-dioxane-2-one (MAC) and 5-methyl-5-ethyloxycarbonyl-1,3-
dioxane-2-one (MEC). Practical reaction methodologies and work up conditions were 
established which circumvented the typically high polydispersities associated with Sn catalysts. 
 
 
 
Development of reaction conditions for polycarbonate homopolymers and allyl-containing 
copolymers 
 
While metal catalyzed ring opening polymerizations of polyesters are well studied, the 
polymerization of polycarbonates with Sn(OTf)2 has not been investigated yet. In general, the 
 
Figure III-1. 
1
H NMR spectra of MEC homopolymer at the beginning of a reaction (top) and 
towards the end of a reaction (bottom) using benzyl alcohol as initiator. 
initiator
monomer monomer + polymer
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incorporation of functionalized monomers has been easier since the ring opening polymerization 
reaction is not impaired by the position of the functional group in the monomer. In the past, one 
of the limitations to study polymerization methods and conditions has been the rather low-
yielding syntheses of functionalized carbonate monomers, but recent improvements made these 
monomers more accessible.
22
 The homopolymerization of 5-methyl-5-ethyloxycarbonyl-1,3-
dioxane-2-one  (MEC) was first conducted in solution either in THF or DMF at room 
temperature. However, polymerization times extended over a week, and therefore faster reaction  
 
 
 
times were sought. Although tin(II) triflate is active at room temperature, elevated temperatures  
were employed  for bulk polymerizations. Consequently, homopolymerizations performed at 70 
°C in bulk were complete after 3 days and yielded polymers with excellent molecular weight 
control and narrow polydispersities. Initially, benzyl alcohol was utilized as the polymer 
 
Figure III-2. 
1
H NMR spectra of MEC homopolymer at the beginning of a reaction (top) and 
towards the end of a reaction (bottom) using 3-methyl-1-butanol as initiator. 
 
monomer monomer + polymer initiator
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initiator, but the compound eventually showed signs of degradation at higher polymerization 
temperatures as indicated by multiplet formation and reduction of the benzyl protons as seen in 
the 
1
H NMR (Figure III-1). In contrast, 3-methyl-1-butanol is less sensitive towards various 
polymerization conditions and the characteristic NMR peaks can be more reliably analyzed in 
the presented polymerization studies (Figure III-2). The controlled nature of the polymerization 
was also verified in the linear relationship of the monomer conversion and the number average 
molecular weight (Mn) (Figure III-3).  
 
 
 
The copolymerization with 5-methyl-5-allyloxycarbonyl-1,3-dioxane-2-one (MAC)  
showed, as expected, a well-controlled incorporation of MAC at a 20% monomer feed ratio as 
summarized in Figure III-4. As pointed out, functionalities on carbonate monomers do not 
 
Figure III-3. Number-average molecular weight (Mn) against % monomer conversion for the 
homopolymerization of MEC as determined by 
1
H NMR.  
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interfere with the catalyst during the ring-opening polymerization process, and the incorporation 
is not as challenging as experienced with α-functionalizations on the valerolactone ring.  
 
 
 
Synthesis of polyester homopolymers and allyl-containing copolymers 
The initial conditions of the homopolymerization of δ-valerolactone included a monomer 
concentration of 8.7M in dichloromethane with 3.2 x 10
-3
 molar equivalents of tin(II) triflate as 
catalyst. The polymerization was living and controlled over a broad molecular weight range with 
narrow polydispersities of 1.08 as illustrated in Figure III-5. Therefore, the same conditions were 
chosen to test the polymerization of copolymers of δ-valerolactone (vl) with α-allyl-δ-
 
Figure III-4. Top: Gel permeation chromatography traces of copolymerization of MEC and 
MAC. Bottom: 
a
All polymerizations were completed at 70°C in bulk conditions.  
b
Mn at full 
conversion. 
c,e
Determined by NMR. 
d
Determined by GPC. 
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valerolactone (avl). Copolymers yielded slightly higher polydispersities, but interestingly the 
incorporation of α-allyl-valerolactone monomer was poor. For example, a calculated 10% 
incorporation of avl yielded 3% incorporation, and an attempted incorporation of 5% yielded 1% 
(Figure III-6). The reactions were typically run for one hour until the polymerization stopped 
stirring. However, a 20% feed ratio of the allyl monomer resulted in the polymerization 
becoming viscous but would not solidify. Nevertheless, the viscous mixture could be precipitated 
and yielded a white powder like the other homo and copolymers. Therefore, the polymerization 
 
 
 
Figure III-5. Top: Number-average molecular weight (Mn) against % monomer conversion 
for the homopolymerization of valerolactone. Bottom: 
a
Polymerizations were completed in 
dichloromethane at 25°C, [monomer] = 8.7 M. 
b
Mn at full conversion. 
c
Reactions were 
precipitated and immediately subjected to NMR analysis. 
d
GPC against poly(styrene) 
standards in THF at 1 mL min
-1
. 
e
Determined by NMR analysis.  
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was allowed to run overnight to determine if the increased reaction time would lead to higher avl 
incorporation. When the reaction time was increased to 15 hours, avl incorporation increased up 
to 80% of the desired incorporation (Figure III-6).  
 
 
 
It is known that α-allyl-valerolactone is a challenging monomer to copolymerize and 
incorporate because of the substitution in α- position that can influence the insertion ring opening 
polymerization mechanism of the ester group. To improve avl incorporation, a more dilute 
reaction concentration was investigated (6.6 M). Consequently, the reaction times increased, but 
the avl incorporation into the polymers increased while polydisperisities remained low. As 
shown in Figure III-7, the polymerization has a molecular weight control over low and high 
molecular weight polymers of 2.5k, 5k, and 20k and yielded narrow polydispersities of 1.14 to 
1.19. Additionally, we conducted the homopolymerization of valerolactone to determine the 
effect of the dilution. The control of polymerization remained the same with a slight 
 
Figure III-6. Copolymerization of δ-valerolactone and α-allyl-δ-valerolactone. 
a
Polymerizations were completed in dichloromethane at 25°C, [monomer] = 8.7 M. 
b
Mn at 
full conversion. 
c,e
Determined by NMR. 
d
Determined by GPC.  
 
39 
 
improvement of the polydispersity to 1.15.  The living polymers were precipitated twice in 
methanol to remove any unreacted monomers but also to remove the reactive Sn endgroup.
23
 The 
methanol exchanges with the Sn catalyst at the chain end of the polymer thereby successfully 
removing the reactive catalyst from the terminal end of the polymer.
24
 However, since residual 
tin was detected using elemental analysis (88 ppm), efforts were sought to decrease the amount 
of catalyst used. As a result, it was determined that similar polyester copolymers with excellent 
avl incorporation and low polydispersities could be formed using 10-fold less Sn(OTf)2 catalyst. 
Therefore, an exact amount of catalyst isn’t required to form excellent polymers; rather, any 
amount of catalyst within this range will suffice. 
 
 
 
Figure III-7. Top: Gel permeation chromatography traces of copolymerization of δ-
valerolactone and α-allyl-δ-valerolactone. Bottom:  aPolymerizations were completed in 
dichloromethane at 25°C, [monomer] = 6.6 M. 
b
Mn at full conversion. 
c,e
Determined by 
NMR. 
d
Determined by GPC.  
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Conclusion 
In this work, we have developed a new, practical methodology to prepare functionalized 
polyester and polycarbonate homo and copolymers using Sn(OTf)2 as catalyst and 3-methyl-1-
butanol as initiator with excellent control over the molecular weight and narrow polydisperisties. 
Reaction concentration was found to be critical to incorporate challenging monomers such as δ-
allyl-valerolactone in the desired monomer ratios. Poly(valerolactone, α-allyl δ-valerolactone) 
copolymers could be prepared with excellent incorporation of the α-allyl-valerolactone monomer 
using a monomer concentration of 6.6 M in dichloromethane. Interestingly, bulk conditions for 
the polycarbonate polymerization were found to be preferential compared to traditional solution 
conditions. Bulk polymerizations of polycarbonates showed excellent control over molecular 
weight, narrow polydispersities, and predictable incorporation of functional groups such as 5-
methyl-5-allyloxycarbonyl-1,3-dioxane-2-one (MAC) at 70 °C. The purification of polymer in 
methanol removes the reactive metal catalyst chain end from the living chain end via an 
exchange reaction.  
 
 
 
Figure III-8. Number-average molecular weight (Mn) and polydispersity against initial 
monomer-to-initiator ratio ([M]0/[I]0) for the copolymerization of MEC/MAC (20%) and δ-
valerolactone/α-allyl valerolactone (10%). 
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The linear correlation between number-average molecular weight (Mn) of copolymers 
MEC with 20% MAC and δ-valerolactone with 10% α-allyl valerolactone against [M]0/[I]0 while 
maintaining low PDI’s demonstrates that both polymerizations are well controlled (Figure III-8).  
The advantage of these methods is their practicality and accurate preparation of polymers to 
build refined biomaterials and nanostructures. Since the allyl functionality was successfully 
incorporated into the polymer, we believe other functionalized carbonate and ester monomers 
can be successfully introduced into similarly controlled polymers using the polymerization 
methods described such as alkyne and chloro groups. Although polycarbonates have been used 
for decades, the ability to synthesize these materials with practical methods allows them to 
become a critical part of very sophisticated materials such as hydrogels for drug delivery 
applications. 
 
Experimental 
Materials 
Tin(II) trifluoromethanesulfonate was obtained from Strem Chemicals Inc. and used as received. 
5-methyl-5-ethyloxycarbonyl-1,3-dioxane-2-one  (MEC) and 5-methyl-5-allyloxycarbonyl-1,3-
dioxane-2-one (MAC) were synthesized as reported previously and recrystallized several times 
before use.
25, 26
 δ-valerolactone (vl) was obtained from Sigma Aldrich and vacuum distilled 
before use. α-allyl-δ-valerolactone (avl) was synthesized as reported previously5 and vacuum 
distilled before use. Dichloromethane (anhydrous), 3-methyl-1-butanol (anhydrous), and 
CDCl3/TMS were obtained from Sigma Aldrich and used as received. Spectra/Por® Dialysis 
membrane was purchased from Spectrum Laboratories Inc.  
 
42 
 
Characterization 
1
H NMR and 
13
C NMR spectra were obtained from a Bruker AC400 Fourier Transform 
Spectrometer, with CDCl3/TMS as the solvent. Gel permeation chromatography (GPC) was 
carried out with a Waters chromatograph system equipped with a Waters 2414 refractive index 
detector, a Waters 2481 dual λ absorbance detector, a Waters 1525 binary HPLC pump, and four 
5 mm Waters columns (300 mm x 7.7 mm), connected in series with increasing pore size (100, 
1000, 100,000 and 1,000,000 Ǻ respectively). All runs were performed with dimethylformamide 
(DMF) or tetrahydrofuran (THF) as the eluent at a flow rate of 1 mL/min.  
 
General MEC Homopolymer Synthesis 
A 25-mL round bottom flask was equipped with stir bar, capped with rubber septum, flame dried 
and nitrogen purged. Sn(OTf)2 (7.0 mg, 0.0168 mmol) was added to the flask, and the flask was 
nitrogen purged once more. 3-methyl-1-butanol (5.8 uL, 0.0531 mmol) was added to the reaction 
flask via microsyringe, and the catalyst/initiator mixture was allowed to stir at room temperature 
for 30 minutes. MEC (0.500 g, 2.657 mmol) was added to the flask and allowed to stir in 70 °C 
oil bath for 87 hours. Polymer was purified by precipitation into methanol or by using 
Spectra/Por dialysis membrane (MWCO = 1,000 Da) against dichloromethane/methanol to yield 
colorless polymer (Theoretical Mn = 18,800 Da, NMR Mn = 18,400 Da, PDI = 1.11, yield = 
0.460 g). 
1
H NMR (400MHz, CDCl3/TMS, ppm) δ: 4.40-4.15 (m, -OC(O)OCH2), 1.30-1.22 (m, 
CH3, -OCH2CH3), 0.93-0.91 (d, 3-methyl-1-butanol, -OCH2CH2CH(CH3)2). 
 
General MEC, MAC Copolymer Synthesis 
A 1-dram vial was equipped with stir bar, capped with rubber septum, flame dried and nitrogen 
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purged. Sn(OTf)2 (3.5 mg, 0.0084 mmol) was added to the vial, and the vial was nitrogen purged 
once more. 3-methyl-1-butanol (11.4 uL, 0.105 mmol) was added to the reaction vial by 
microsyringe, and the catalyst/initiator solution was allowed to stir at room temperature for 30 
minutes. MEC (0.395 g, 2.099 mmol) and MAC (0.105 g, 0.5245 mmol) were added to the vial, 
melted at 70 °C, and allowed to stir in 70 °C oil bath for 71 hours when stirring became greatly 
impeded. The resulting polymer was purified by precipitation into methanol or by dialysis using 
Spectra/Por dialysis membrane (MWCO = 1,000 Da) against methanol/dichloromethane to yield 
colorless polymer (Calculated Mn = 4,800 Da, NMR Mn = 6,500 Da, PDI = 1.11, yield = 0.359 
g) theoretical allyl incorporation = 20.0%, actual allyl incorporation = 19.0%). 
1
H NMR 
(400MHz, CDCl3/TMS, ppm) δ: 5.91-5.85 (m, -OCH2CHCH2), 5.34-5.23 (m, -OCH2CHCH2), 
4.64-4.62 (m, -OCH2CHCH2), 4.40-4.15 (m, MAC & MEC, -OC(O)OCH2), 1.30-1.22 (m, MAC 
& MEC, CH3; MEC, -OCH2CH3), 0.93-0.91 (d, 3-methyl-1-butanol, OCH2CH2CH(CH3)2). 
13
C 
NMR (400 MHz, CDCl3/TMS, ppm) δ: 174.1, 172.1, 154.9, 154.4, 131.7, 118.5, 68.6, 65.9, 
64.7, 61.2, 50.8, 48.2, 46.5, 24.8, 22.4, 17.5, 14.1. 
 
General Valerolactone Homopolymer Synthesis (6.6 M) 
A 25-ml round bottom flask was equipped with a stir bar, capped with a rubber septum, nitrogen 
purged and flame dried. Sn(OTf)2 (6.7 mg, 0.016 mmol) was weighed directly into the flask. The 
flask was sealed with rubber septum and nitrogen purged. 3-methyl-1-butanol (21.8 uL, 0.200 
mmol) and 0.272 mL anhydrous dichloromethane was added to the flask via syringe, and the 
catalyst/initiator solution was allowed to stir at room temperature for 30 minutes. Delta-
valerolactone (0.500 g, 4.994 mmol) was added to the solution and stirred 5 hours. Polymer was 
purified by precipitating into cold methanol to yield white product (Theoretical Mn = 2,500 Da, 
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NMR Mn = 2,400 Da, PDI = 1.19, yield = 0.451 g). 
1
H NMR (400MHz, CDCl3/TMS, ppm) δ: 
4.08 (m, -OCH2), 2.34 (m, -O(O)CH2CH2), 1.68 (m, -CHCH2CH2-), 0.93-0.91 (d, 3-methyl-1-
butanol, -OCH2CH2CH(CH3)2). 
 
General Valerolactone, allyl-Valerolactone Copolymer Synthesis  
A 25-ml round bottom flask was equipped with a stir bar, capped with a rubber septum, nitrogen 
purged and flame dried. Sn(OTf)2 (6.4 mg, 0.015 mmol) was weighed directly into the flask. The 
flask was sealed with rubber septum and nitrogen purged. 3-methyl-1-butanol (21.8 uL, 0.200 
mmol) and 0.243 mL anhydrous dichloromethane was added to the flask via syringe, and the 
catalyst/initiator solution was allowed to stir at room temperature for 30 minutes. δ-valerolactone 
(0.433 g, 4.322 mmol, vl) and δ -allyl-δ-valerolactone (0.067 g, 0.477 mmol, avl) were added to 
the solution, and reaction was allowed to stir for 21 hours. Polymer was purified by precipitating 
into cold methanol to yield white product (Theoretical Mn = 2,500 Da, NMR Mn = 2,800 Da, 
PDI = 1.19, yield = 0.381 g, theoretical avl incorporation = 10.0%, actual avl incorporation = 
9.3%). 
1
H NMR (400MHz, CDCl3/TMS, ppm) δ: 5.75-5.70 (m, -CH=CH2),  5.10-5.01 (t, J = 
18.2 Hz, J = 11.5 Hz, 2H, -CH=CH2), 4.08 (m, -OCH2), 2.34 (m, vl, -O(O)CH2CH2; avl,  
-O(O)CHCH2CH=CH2, -CHCH2CH=CH2),  1.68 (m, avl & vl, -CHCH2CH2), 0.93-0.91 (d, 3-
methyl-1-butanol, -OCH2CH2CH(CH3)2). 
13
C NMR (400 MHz, CDCl3/TMS, ppm) δ: 175.2, 
173.4, 135.2, 117.1, 64.1, 44.9, 37.4, 33.8, 28.1, 26.5, 25.1, 22.5, 21.3. 
 
Number average molecular weight (Mn) – monomer conversion experiment 
Valerolactone and MEC homopolymers were prepared as mentioned previously, but CDCl3 was 
used as solvent for the valerolactone polymerization in order to be used for immediate NMR 
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analysis. At predetermined time points depending on the polymer reaction, a small amount of the 
polymerization was removed and analyzed immediately by 
1
H NMR.  
 
Termination of Polymerization  
Polymerizations were terminated by precipitating twice in cold methanol, effectively removing 
the catalyst from the terminal end of the polymer. Polymers were analyzed by ICP atomic 
emission techniques (Applied Technical Services, Inc.) Elemental analysis: 88 ppm Sn. 
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CHAPTER IV 
 
 
 
POLYESTER NANOSPONGE FORMATION FOR PACLITAXEL NANOSOLUBILIZATION  
 
AND TAILORED DRUG RELASE 
 
 
 
Introduction 
 
In general, solubility is the primary clinical limitation for most drugs, and strategies to 
improve drug solubility are paramount for the continued improvement of therapeutics. 
Biodegradable polymeric nanoparticles utilized as a controlled release formulation of drugs is an 
effective strategy for the improvement of numerous therapeutic applications.
1, 2,
 
3
  Nanoparticles 
are excellent drug delivery vehicles due to their modular synthesis that allows for complete 
customization of the vehicles to meet various applications in which the therapeutic could 
otherwise be limited by size or solubility. For example, chemotherapeutics such as paclitaxel 
belong to class IV of the biopharmaceutics classification system (BCS) because they have low 
solubility and low permeability, which leads to poor bioavailability.
4
 Ideally, a single therapeutic 
dose would allow for a high dissolution of the drug and an exact amount of drug to release in a 
specific amount of time to meet the individual needs of any patient.  
Currently, many approaches synthesize a single type of vehicle that allows for a single, or 
slightly adjustable, drug release rate and then identify suitable biomedical applications. Also, 
drug release is often rapid, especially within the first 48 hours. For example, multilayered 
nanoparticles from block copolymers or nanoparticles mixed with surfactant result in rapid 
release profiles, and release rates can only be controlled by copolymer makeup and type of 
surfactant used, respectively.
5,
 
6,
 
7
 Likewise, micelles offer quick and easy preparation, but often 
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lead to rapid release of drug.
8,
 
9,
 
2
 One strategy has been to design prodrugs with stimuli-
responsive covalent bonds to attach the drug to the carrier with a programmed release.
10
 
Although this strategy is very successful for selected drugs, the high specification prevents a 
broader application for a range of established and newly developed drugs which imposes a major 
limitation.
11,
 
12
  
Alternatively, the next generation of drug delivery will allow complete customization of a 
single platform vehicle that can be easily tuned to meet any therapeutic need. Therefore, we 
investigated the synthesis of biodegradable, polyester nanoparticles, the ability to encapsulate 
and nanosolubilize paclitaxel encapsulation, and for the first time, demonstrate the ability to 
control the release of paclitaxel by adjusting the single parameter of the particles’ crosslinking 
density. Additionally, particles with different densities can be mixed to yield various rates of 
release that can be fast or slow depending on the specific application. The ability of these 
particles to withstand simulated gastric fluid allows for the possibility of an oral drug delivery 
route. 
 
Results and Discussion 
Polyester nanosponges were prepared with varied degrees of crosslinking densities of 
4%, 7% and 10% and an average nanoscopic size of 100 nm. The crosslinking density and the 
influence towards the release kinetics of paclitaxel, a BCS class IV drug, for individual particles 
and a mixture of particles from two different crosslinking densities are investigated in buffer and 
gastrointestinal fluid and employs fully adjustable release rates suitable for intravenous and oral 
delivery. Herein, we present the synthesis of biodegradable nanoparticles capable of paclitaxel 
entrapment, and we demonstrate the ability to control release of paclitaxel by adjusting the single 
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parameter of the crosslinking density of the particles. Additionally, particles with different 
densities can be mixed to yield various rates of release that can be fast or slow depending on the 
specific application. The ability of these particles to withstand simulated gastric fluid allows for 
the possibility of an oral drug delivery route while the therapeutic remains amorphous in the 
nanoparticle.  
 
Synthesis of epoxide-functionalized polyesters – precursors to nanosponge formation 
 
 
 
Epoxide functionalized polyester precursors were prepared by first synthesizing allyl-
valerolactone, valerolactone copolymers (poly(avl,vl)) described previously
13
, and then 
converting the allyl group to an epoxide using meta-chloroperoxybenzoic acid (mCPBA) to yield 
poly(evl,vl). This reaction was performed using 1.2 equivalents mCPBA per alkene in 
dichloromethane at an alkene concentration of 0.065 M for 48 hours. It was determined that 
washing the resulting polymer in saturated sodium bicarbonate effectively removed the acid 
while still achieving good yields (greater than 70%). This was significantly more effective than 
 
Figure IV-1. Epoxidation of the allyl group at full conversion (top) or partial conversion 
(bottom) based on equivalents of mCPBA. 
53 
 
precipitating in diethyl ether which often required multiple precipitations in large volumes of 
ether resulting in yields between 50-70%. In this study, the conversion of allyl to epoxide was 
100% as indicated by 
1
H NMR analysis. However, partial epoxidation is possible by reducing the 
equivalents of the mCPBA or by reducing the overall reaction time. The ability to adjust this 
conversion allows a fine tuning of the polyester precursor that will be used to synthesize the 
resulting nanoparticle. This is especially important for applications that require further 
modifications of the resulting nanoparticles. For example, partial epoxidation of the polyester 
allows a quantifiable number of allyl groups remaining which can be used to attach targeting 
peptides to the surface of the nanoparticle using thiolene click chemistry. The ability to undergo 
partial epoxidiation can also be important to achieve a desired amount of epoxide which is 
responsible for the nanoparticles’ crosslinking density. 
 
 
 
 
Figure IV-2. 
1
H NMR spectra of poly(avl,vl) before (bottom) and after epoxide conversion 
(middle) and of nanosponge after amine-epoxide crosslinking (top). 
Allyl
Epoxide
Crosslinker
Poly(avl,vl)
Poly(evl,vl)
Nanosponge
54 
 
Synthesis of polyester nanosponges via amine-epoxide chemistry 
 Nanoparticles were synthesized via intermolecular crosslinking between a bisamine 
crosslinker and epoxide functionalized polyesters at an epoxide concentration of 3.24 x 10
-3
 M 
for 12 hours at 45 °C (Figure IV-3). Epoxide functionality within the polyesters ranged from 4-
10% while the equivalents of amine per epoxide used remained constant (1.5 amines per 
epoxide). The definition of crosslinking density is based on the amount of epoxide present in the 
polyester precursor.
14
 In other words, the percentage of epoxide in the polyester precursor 
determined the crosslinking density of the subsequent nanoparticle. The slight excess of amine 
crosslinker is useful to ensure that free amines will remain within the nanonetwork after the 
nanoparticles are formed, and these amines can also be used for post-modification reactions such 
as attaching imaging dyes using NHS-ester chemistry.  
 
 
 
Figure IV-3. Intermolecular crosslinking reaction between epoxide functionalized polyesters 
and bis(amine) polyethylene glycol crosslinker to form functionalized nanosponges. 
CH2Cl2
45  C, 12 hrsX%
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 Although 10% crosslinking density was the highest crosslinking in this study, the average 
nanoparticle size remained similar compared to particles with less dense networks. For example, 
particles with 9.8% crosslinking density were 103 ± 21.5 nm and particles with 4.1% 
crosslinking density were 107 ± 16.4 nm (Figure IV-4). Previous studies
15
 suggested particle size 
would increase with increased epoxide functionality; however, the variability within this range of 
epoxide functionality does not appear to exhibit a significant effect on particle size. In other 
words, polymers containing more than 10% epoxide may be necessary to synthesize particles of 
greater size using these conditions. This nanoparticle size was chosen as it considered the ideal 
size not only for intravenous injections to avoid accumulation in organs such as the liver, as 
often observed for larger particle sizes, but also the ideal size to cross the intestinal epithelial 
layer in oral drug delivery approaches.
16,
 
17,
 
18,
 
19
  
 
 
 
As therapeutics become increasingly hydrophobic, a smart formulation that a.) keeps the 
therapeutic from crystallizing and in an amorphous state, b.) maintains the maximum ability to 
 
Figure IV-4. TEM analysis with representative images of nanosponges with three different 
crosslinking densities of 4.1%, 7.1% and 9.8%. 
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cross the intestinal barrier, c.) does not accumulate in organs once circulating in the bloodstream,  
and  d.) has adjustable release profiles represents the ideal therapeutic carrier. Moreover, it has 
been reported that 100 nm particles are ideal for oral drug delivery and are also superior to 50 
nm, 200 nm and 500 nm particle sizes.
17
 With this, the 100 nm particle range can be prepared to 
meet the needs of therapeutic delivery in oral and IV administration. 
 
Nanosolubilization of Paclitaxel 
 
 
 
The prepared particles were loaded with paclitaxel as a model drug after the nanoparticle 
was formed (post-loading) in a developed nanosolubilization method
20
 which is demonstrated in 
Figure IV-5. Post-loading can be accomplished due to the full solubility of both the particle and 
drug in DMSO to form a homogenous solution. Once added to the aqueous environment, 
 
Figure IV-5. Nanosolubilization method for encapsulating drugs within the nanosponge. 
Water
(Vit E-TPGS)Drug
+
Homogenous 
DMSO 
solution
NANOSOLUBILIZATION
2. Centrifuge
3. Multiple washes 
with water
4. Lyophilization yields white 
powder of nanosolubilized drug
5. Readily dispersed in aqueous 
buffer  for direct administration
1. Drop- in
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precipitation occurs, and the drug incorporates into the polyester nanosponge via hydrophobic 
interactions. D-α tocopherol polyethyleneglycol(1000) succinate (Vit E-TPGS) was utilized to 
enhance the hydrophilicity of the nanoparticle surface and increase circulation half-life by 
preventing premature clearance and immune response during in vivo applications.
21,
 
22
 The 
amount of the formulated paclitaxel into the particle was determined by HPLC analysis, and an 
average of 13% paclitaxel (wt/wt) in the final product could be achieved. 
 
X-ray diffraction (XRD) and differential scanning calorimetry (DSC) analysis of 
nanosponge and encapsulated paclitaxel 
 
To determine if the polymeric nanonetwork of the particle prevents the crystallization of 
the drug which allows for better dissolution in the biological environment, DSC and XRD 
measurements were undertaken (Figure IV-6 top). The XRD spectrum of paclitaxel shows 
numerous peaks, particularly in the 2θ range of 5-25 °C,  which are in accord with published data 
of paclitaxel’s unique crystallization pattern.23 These peaks are also visible in a physical mixture 
of paclitaxel and polyester nanoparticle (13% ptx wt/wt), indicating the paclitaxel remains 
crystalline when physically mixed with the nanoparticle, as expected. However, these peaks are  
not visible in the encapsulated paclitaxel sample, indicating the drug is in an amorphous state 
once encapsulated, and is in agreement with other published studies.
24
 The amorphous state of 
the encapsulated paclitaxel is also demonstrated using differential scanning calorimetry (Figure 
IV-6 bottom). The DSC curve of paclitaxel shows an endothermic melting point at 223 °C which 
matches previously published data.
23
 However, this melting point is absent in the encapsulated 
paclitaxel due to the amorphous state of the drug in this formulation. These results suggest that 
confining the drug to the nanoscale through nanoparticle encapsulation decreases the drug 
crystallinity which allows for improved water solubility.  
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Paclitaxel release from particles with 4, 7, and 10% crosslinking density in PBS 
To investigate the influence of the varied crosslinking densities, which also varies the 
percentiles of ethylene oxide ratios present in the particle, drug release kinetics were first 
performed PBS employing the individual particles with 4%, 7% and 10% crosslinking density. 
Paclitaxel was chosen as a model drug since it is one representative of the BCS class IV and also 
is a powerful chemotherapeutic.
4
 For BCS class II drugs, which have a low solubility but 
 
Figure IV-6. Top: XRD analysis of ptx, nanoparticle/ptx mixture, encapsulated ptx (NP-
PTX), and nanoparticle alone (NP). Bottom: DSC analysis of ptx, encapsulated ptx, and 
nanoparticle alone. Endotherms are down. 
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typically are permeable, successful high saturation carriers such as cellulose esters and 
derivatives are sufficient to achieve a higher bioavailability.
25,
 
26
 In contrast, BCS IV drugs 
require both high solvation and tailored carriers in the optimized size to permeabilize and release 
the drugs in controlled release mechanisms once in the blood, tissue or cell.  
 
 
 
Paclitaxel release from nanoparticles with 4, 7, or 10% crosslinking density in PBS (pH 
7.4, 0.1% Tween-80 v/v) at 37 °C is shown in Figure IV-7. Tween-80 was utilized in the release 
buffer as it prevents binding of free drug to the vessel during the experiment.
27
 Critically, 
different release rates were achieved by simply adjusting the crosslinking density of the particle, 
with the fastest release from a 4% and the slowest from a 10% crosslinked particle during the 21 
day release period.  Since the crosslinking density originates from the linear polyester precursor, 
a simple variation of the epoxide percentage allows the observed far reaching effect on drug 
release kinetics.  For example, particles with the lowest crosslinking 4% crosslinking density 
 
Figure IV-7. Left: Cumulative release of individual and a mixture of particles loaded with 
paclitaxel measured in PBS. Right: Average released paclitaxel concentration per day for each 
release profile.  
 
Crosslinking
Density
Average [PTX] 
released per day
4% 6.3 µM
7% 2.9 µM
10% 2.0 µM
Mix 4%, 10%) 1:1 2.9 µM
Mix(4%, 10%) 4:1 4.4 µM
(
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released 95% of the drug during the 21 days. On the other hand, a 10% crosslinked particle only 
released 29% total drug after 21 days.  Interestingly, the least dense network 4% showed a higher 
amount of drug released after 5 hours (18%), compared to the relatively denser network (10% 
crosslinking) that showed only 8% paclitaxel release after 5 hours. This trend is also seen in the 
release curve of a 7% crosslinked particle that initially releases 13% paclitaxel after 5 hours, but 
the sustained release rate is very similar to that of the 10% crosslinked particle. The initial higher 
release can be clinically desirable to achieve high plasma concentrations similarly seen from an 
IV bolus injection or, in the case of cancer therapeutics, to allow local high drug concentrations 
at the tumor. However, the initial release rates are significantly lower than those for self-
assembled poly(lactic-co-glycolic acid) (PLGA) particles in which an initial drug release can be 
over 40% in the first 48 hours.
28
 Furthermore, a self-assembled system allows rather limited 
variation of release rates guided in part by the amount of surfactant used.
7
 Overall, we conclude 
from these release studies that drug release rates can be controlled and adjusted by modulating 
the single parameter of the particle’s crosslinking density to achieve faster or slower release rates 
in vitro.   
In general, in vitro studies suggest that paclitaxel duration has a greater effect on 
cytotoxicity compared to paclitaxel concentration
29,
 
30
; therefore, a sustained release of low 
paclitaxel concentrations could potentially be investigated as an alternative to the currently 
established regimens. For patients with non-small cell lung carcinoma, the recommended dose of 
paclitaxel is 135 mg/m
2
 through a 24 hour infusion every three weeks, and steady-state plasma 
concentrations typically range between 0.12-2.17 µM.
31
 It has also been reported that 
myelosuppresion becomes more severe when plasma concentrations exceed 0.05-0.1 µM for 
long periods of time.
32,
 
33,
 
34
 In this study, the average concentration of released paclitaxel per 24 
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hours ranged from 6.3 µM (using the 4% crosslinked particles) to 2.0 µM (using the 10% 
crosslinked particles). However, it must be noted that these concentrations are dependent on the 
volume of PBS used which is based on the initial concentration of 0.15 mM paclitaxel that was 
chosen. Therefore, these concentrations of released paclitaxel are obviously not an indication of 
what plasma concentrations would be in vivo and should not be viewed as such. For in vivo 
purposes, the encapsulated paclitaxel dose can be scaled up or down to achieve the desired 
plasma concentrations.  
 
Paclitaxel release from combined particles with different densities 
Drug release rates could also be adjusted by combining particles that contained different 
crosslinking densities. For example, when particles with 4% crosslinking were mixed in a 1:1 
ratio with particles with 10% crosslinking density, the overall release rate, as expected, was 
neither as fast as 4% crosslinked particles nor as slow as 10% crosslinked particles. Rather, this 
mixture allowed two simultaneous release rates that resembled an overall rate similar to particles 
with 7% crosslinking density. This was confirmed by repeating the experiment but using a 4:1 
ratio of 4% to 10% crosslinked particles. As expected, the overall release rate was faster 
compared to 7% crosslinked particles, but not as fast as 4% crosslinked particles. Although 
paclitaxel was chosen as our model drug, we believe similar results can be achieved with any 
hydrophobic, small molecule drug. These results suggest that by mixing particles of different 
densities in adjusted ratios, the nanosponge intermolecular crosslinking methodology is a 
platform technology in which drug release kinetics can be adjusted to ratios that will serve the 
needs of an individual patient or disease.  
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Paclitaxel release from particles in simulated gastric fluid 
Early studies have shown the potential of the nanosponge for the treatment of various 
cancer types in mouse tumor models as demonstrated by a single type of nanosponge delivered 
intravenously.
35,
 
36
 Since we synthesized particles with the ideal size for an oral drug delivery 
system, we sought to test the release rate in simulated gastric fluid to determine the potential of 
this vehicle to survive the acidic conditions of the stomach from an oral drug delivery 
administration since orally available drugs are the most patient compliant. Although the normal 
stomach emptying time (T1/2) ranges from minutes to several hours
37
, paclitaxel release was 
measured up to 12 hours in simulated gastric fluid (Figure IV-6). Surprisingly, a slow and  
 
 
 
sustained release of paclitaxel was achieved despite the acidic conditions. Only 8% of the drug 
was released after 2 hours and only 13% was released after 12 hours using a particle with 4% 
 
Figure IV-6. Cumulative release of a 4% crosslinked particle loaded with paclitaxel 
measured in simulated gastric fluid (SGF). 
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crosslinking density. This suggests these nanoparticles will not release a significant amount of its 
therapeutic cargo despite the acidic conditions of the stomach. With the ability to maintain 
therapeutic cargo in the stomach while being able to transport across the intestines, the use of 
polyester nanosponges could have a major impact on improving the bioavailability of poorly 
absorbed drugs. 
 
Conclusion 
The presented research assessed the ability of the nanosponges prepared from 
intermolecular chain crosslinking reactions with resulting crosslinking densities of 4%, 7%, and 
10% to serve as platform technology for complete customization of release profiles to meet the 
need of a patient through IV or oral administration. We have demonstrated with paclitaxel, one 
representative of the BCS IV class which is one of the most challenging drug classes that 
includes drugs with low solubility and permeability, can be solvated and formulated without 
crystallization of the drug. Furthermore, drug release kinetics measured in buffer could not only 
confirm that the crosslinking density of the particle is responsible for the variation in release 
rates but also more importantly a fine tuning and customization of unprecedented levels can be 
achieved by mixing particles of different crosslinking densities in varied ratios, as demonstrated 
in two examples. All particles were prepared in a 100 nm size range which is ideal for both IV 
administration and oral delivery of drugs, particularly BCS IV drugs. Investigations of release 
kinetics in simulated gastrointestinal fluid showed a slow release profile that supports the use of 
nanosponges for oral administration of BSC IV class drugs to afford high solubilization, high 
permeability, and a fully adjustable release profile of the therapeutic.   
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Experimental 
Materials 
Meta-chloroperoxybenzoic acid was purchased from Sigma Aldrich and recrystallized in 
methanol before use. Paclitaxel was obtained from LC Laboratories. Phosphate buffered saline 
was obtained from Gibco by Life Technologies and pH was adjusted to 7.4 and supplemented 
with Tween-80 (0.1% v/v). Simulated gastric fluid was prepared by dissolving 2.0 grams sodium 
chloride in 7.0 mL concentrated HCl, diluting to 1.0 L with water, adjusting pH to 1.2, and 
supplemented with Tween-80 (0.1% v/v). Spectra/Por® Dialysis membrane was purchased from 
Spectrum Laboratories Inc. All other materials were obtained from Sigma Aldrich and used as 
received. 
 
Characterization 
Samples for transmission electron microscopy (TEM) imaging were prepared by dissolving 0.5 
mg nanoparticles in 1 mL filtered, deionized water. The samples were sonicated for 30 min and 
stained with 6 drops of 3% phosphotungstic acid. The carbon grids were prepared by slowly 
dipping an Ultrathin Carbon Type-A 400 Mesh Copper Grid (Ted Pella, Inc., Redding, CA) into 
the particle solution three times and air drying the grid at room temperature. A Philips CM20T 
transmission electron microscope operating at 200 kV in bright-field mode was used to obtain 
TEM micrographs of the polymeric nanoparticles. 
1
H NMR spectra were obtained from a Bruker 
AC400 Fourier Transform Spectrometer with CDCl3/TMS as solvent. High-performance liquid 
chromatography (HPLC) was carried out using a Waters chromatograph equipped with a Waters 
2996 variable wavelength photodiode array detector, a Waters 1525 binary HPLC pump, and a 
reverse phase column (100 x 4.6 mm i.d., pore size 5 μm, Thermo Scientific). All runs were 
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performed using an isocratic gradient of water and acetonitrile (1:1 v/v) at a flow rate of 1 
mL/min. X-ray diffraction analysis was performed using a Scintag X1 θ/θ automated powder X-
ray diffractometer with a Cu target, a Peltier cooled solid-state detector, and a zero-background 
Si(510) sample support. Scans were collected at a rate of 1°/min in the 2θ range from 5 to 65°. 
Differential scanning calorimetry was conducted using a TA Instruments Differential Scanning 
Calorimeter (DSC) Model 2920. Samples were added to aluminum pans and non-hermetically 
sealed. All samples scanned between 25 and 250°C at a rate of 10°C/min after equilibrating at 25 
°C.   
 
Polyester nanoparticle synthesis (NP) 
Poly(α-allyl-valerolactone, valerolactone)13 containing 4, 7, or 10% allyl functionality was 
epoxidized by stirring meta-chloroperoxybenzoic acid (mcpba, 1.2 eq per alkene) in CH2Cl2 
(0.065 M alkene) for 48 hours and washing with saturated sodium bicarbonate. Resulting 
polymer was dried under reduced pressure to yield poly(evl-vl) (yield = 75%). 
1
H NMR (400 
MHz, CDCl3/TMS, ppm) δ: 4.08 (m, –OCH2), 2.96-2.91 (m, ), 2.75, (m, ), 
2.47 (m, ), 2.34 (m, evl and vl, –O(O)CH2CH2), 1.68 (m, evl and vl, –CHCH2CH2; evl 
), 0.93–0.91 (d, 3-methyl-1-butanol, –OCH2CH2CH(CH3)2). Nanoparticles were 
formed by refluxing 2,2’-ethylenedioxy-bis(ethylamine) (1.5 amines per epoxide) with poly(evl-
vl) in CH2Cl2 (3.24 x 10
-3
 M epoxide) at 46 °C for 12 hours. For example, a 4% crosslinked 
nanoparticle was formed by adding 2,2’-ethylenedioxy-bis(ethylamine) (7.5 µL, 0.51 mmol) to a 
stirring solution of poly(evl-vl) (0.173 g, Mn = 3,644 Da, 6.83 x 10
-2
 mmol epoxide) containing 
4% epoxide dissolved in CH2Cl2 (21.1 mL). The refluxing mixture stirred for 12 hours at 46 °C. 
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Residual bisamine was removed by dialyzing with Snakeskin Pleated Dialysis Tubing (MWCO 
= 10,000 Da) against CH2Cl2 to yield nanoparticles (NP, 123.8 mg). 
1
H NMR (400 MHz, 
CDCl3/TMS, ppm) δ: The significant change is the disappearance of the epoxide ring protons at 
2.96, 2.76, and 2.47 ppm and the emergence of small, broad peaks at 3.50-3.45 ppm from the 
methylene protons adjacent to the oxygens in the crosslinker and 2.75-2.68 ppm from the 
methylene protons adjacent to the secondary amine after crosslinking. Particles with 7% and 
10% crosslinking densities were synthesized in a similar manner with poly(evl-vl) containing 7% 
and 10% epoxide functionality, respectively, and reacting with 2,2’-ethylenedioxy-
bis(ethylamine) (1.5 amines per epoxide) in CH2Cl2 (3.24 x 10
-3
 M epoxide) for 12 hours at 46 
°C. 
 
Paclitaxel encapsulation into nanoparticles (NP-PTX) 
A solution of nanoparticle (70.0 mg) and paclitaxel (15.4 mg) in DMSO (0.150 mL) was added 
drop-wise to a vortexing solution of aqueous 1% d-α-tocopherol polyethyleneglycol (1000) 
succinate (Vit E-TPGS, 35.0 mL). The resulting precipitation was centrifuged to remove the free 
drug from the encapsulated drug. The precipitation underwent three cycles of centrifugation at 
7830 rpm for 20 minutes and replacing the supernatant each time with fresh deionized water. The 
precipitation was freeze-dried to yield a white powder (13.0% paclitaxel wt/wt determined by 
HPLC detecting at 227 nm). 
 
In vitro drug release 
The release of paclitaxel from the nanoparticles was measured in PBS (pH 7.4) or simulated 
gastric fluid (pH 1.2) containing Tween-80 (0.1% v/v) at 37 °C at a paclitaxel concentration of 
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0.15 mM. For example, a 4% crosslinked nanoparticle containing 13.0% paclitaxel wt/wt (4.8 
mg) was suspended in 5.0 mL PBS (pH 7.4, 0.1% Tween-80 v/v). At each time point, the 
suspension was centrifuged at 7830 rpm for 15 minutes and the supernatant was collected and 
replaced with 5.0 mL fresh buffer. For release studies in PBS, the supernatant at each time point 
was analyzed by HPLC as described in the characterization section. For release studies in 
simulated gastric fluid, the supernatant was neutralized with sodium bicarbonate to pH 7 and 
extracted three times with 5 mL CH2Cl2. The CH2Cl2 was evaporated and the resulting solid was 
dissolved in acetonitrile/water (1:1 v/v) and analyzed by HPLC.  All experiments were 
performed in triplicate. 
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CHAPTER V 
 
NANOSPONGE/POLYGLYCIDOL DUAL DRUG DELIVERY OF MEK INHIBITOR AND 
BONE MORPHOGENETIC PROTEIN 2 FOR IMPROVED BONE HEALING 
 
Introduction 
 Neurofibromatosis 1 (NF1) is an autosomal dominant disease caused by mutations of the 
tumor-suppressor gene NF1
1, 2
, a gene encoding the RAS GTP-ase activating protein 
neurofibromin
3, 4
, and patients with NF1 frequently suffer from skeletal defects including 
decreased bone mineral density, tibia bowing, and impaired bone healing following fracture 
(pseudoarthrosis).
5, 6
 The focal nature of the dysplastic skeletal lesions in NF1 and the identified 
second hit mutations in NF1 detected in biopsies from NF1 pseudarthroses
7
 suggest that a 
restricted population of bone mesenchymal progenitors characterized by NF1 loss of function 
triggers the focal skeletal dysplasia associated with NF1.  In support of this hypothesis, 
neurofibromin is expressed in bone-forming cells and its loss of function leads to chronic and 
uncontrolled RAS-ERK activity in multiple cell lineages, including chondrocytes and 
osteoblasts.
8,
 
9,
 
10
  
Since the etiology of the skeletal disorder is not fully known, treatment is often limited to 
surgical correction or amputation.
11
 Additionally, the development of novel therapeutics remains 
difficult due to the lack of animal models that can recapitulate the complex bone disorder 
associated with NF1. Engineering such a mouse model remains its own challenge since Nf1
-/-
 
mice are embryonic lethal.
12, 13, 14
 However, Elefteriou and coworkers generated a new mouse 
model that lack Nf1 in post-natal Osterix (Osx)-positive osteoprogenitors (Nf1osx
-/- 
mice). This 
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model was generated by crossing mice with Nf1 floxed alleles
15
 and mice expressing the cre-
recombinase under the control of the Osterix (Osx) promoter and Tet
off 
system
16
. These mutant 
mice exhibit reduced stature due to Osx-cre activity in chondrocytes during development
17,
 
18
, 
but are born with a normal size and do not show any short stature phenotype in adults when 
given doxycycline from conception to 2 weeks of age to repress cre-recombinase activity. This 
mouse model can be used to determine if loss of Nf1 function in osteoblast progenitors impairs 
their differentiation in vivo, independent of developmental growth plate factors. 
 Constitutive activation of RAS and ERK are a consequence of Nf1 deficiency, and this is 
believed to play a major role in osteoclastogenesis and improper healing in response to fracture. 
Recently, studies showed that combination treatment of bone morphogenetic protein 2 (BMP2) 
and bisphosphonates could improve bone production in Nf1
+/-
 mice, but did not rescue the 
impaired signaling pathway.
19
 BMP2 can promote cell differentiation through either the 
RAS/ERK or SMAD signaling pathways; however, the constitutive ERK activity caused by Nf1 
deficiency blunts the response to the osteogenic property of BMP2 since ERK negatively 
regulates the SMAD signaling pathway. Therefore, a MEK inhibitor would allow some control 
or negative regulation of the constitutively active ERK. In vitro results indicated neither 
therapeutic alone could rescue the signaling defects, but rather both BMP2 and a MEK inhibitor 
were required simultaneously. 
 BMP2 is commercially available and is a current therapeutic option for numerous bone 
healing applications.
20, 21
 However, BMP2 is cleared within hours upon administration and a 
sustained release technology is desired to circumvent frequent dosing. Trametinib, a MEK 
inhibitor (GSK), is completely insoluble in water and therefore is difficult to administer 
systemically. A sustained release of MEK inhibitor is also desired in order to continuously act on 
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the healing bone tissue in conjunction with BMP2. Therefore, a dual drug delivery system is 
required that would allow the release of two different classes of therapeutics simultaneously. The 
polyester nanosponge is an excellent vehicle to nanosolubilize the MEK inhibitor to decrease its 
crystallinity and increase its water solubility. Also, the nanosponge allows for a tailored release 
of the MEK inhibitor. However, an alternative material is required for the sustained release of a 
protein growth factor. For example, polyglycidol is a semi-branched, PEG-like polymer that can 
act as a matrix for larger biologically active structures. In this way, BMP2 can slowly diffuse out 
of the polyglycidol matrix, and at the same time, MEK inhibitor will be released from the 
nanosponge. The success of this system is not only a significant achievement from a drug 
delivery and nanotechnology standpoint but also for the development of new technologies for 
bone healing applications and novel treatments for diseases that are otherwise difficult to treat 
such as NF1. 
 
Results and Discussion 
Encapsulation of MEK inhibitor in polyester nanosponge 
 Nanoparticles containing 4% crosslinking density were synthesized as previously 
described.
22
 A lower crosslinking density was chosen since maximum release of the drug was 
desired within the first three weeks. MEK inhibitor was encapsulated into the particles using the 
nanosolubilization process described earlier. Although the MEK inhibitor is hydrophobic, its 
solubility in DMSO is not as high compared to paclitaxel and thus additional DMSO was 
required to fully solubilize for encapsulation. Because of this, precipitation was more 
challenging, and the final product only contained 6.4% wt/wt drug after an 18% drug loading 
76 
 
ratio. Nevertheless, the drug was successfully encapsulated and could be incorporated into the 
final formulation at a therapeutically relevant concentration. 
 
 
 
BMP2 formulation in polyglycidol and dual drug delivery formulation 
 Polyglycidol is a semi-branched, water-soluble, and anti-fouling polymer. Because of its 
polyethyleneglycol-like characteristics, biocompatibility, viscosity, and semi-branched nature, 
polyglycidol was chosen to act as a matrix for the incorporation of biologically active peptides 
and proteins, in this case BMP2. Polyglycidol was synthesized by Benjamin Spears of the Harth 
Laboratory (Vanderbilt University) as previously reported.
23
 Since vacuum-dried polyglycidol is 
very viscous, phosphate buffered saline (PBS) was added to reduce its viscosity in order to load 
into an insulin syringe. A defined volume of PBS was added until the mixture could successfully 
be taken up by an insulin needle, and this exact ratio of PBS to polyglycidol served as a measure 
 
Figure V-1. Illustration of encapsulated MEK inhibitor with BMP2 in polyglycidol matrix. 
Over time, BMP2 and MEK inhibitor is released simultaneously. 
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for all formulations. It was determined that a polyglycidol concentration of 0.46 g/mL in PBS 
served as the maximum concentration that could be taken up into the insulin needle for injection. 
With this viscosity, it is believed the injected material will remain at the injection site and slowly 
dissolve over time while the drugs are released. 
 The purpose of the dual drug delivery formulation is to locally release both the BMP2 
and the MEK inhibitor at the fracture site to allow synergistic therapeutic effects for up to a week 
(Figure V-1). Each injection contained 10 µg BMP2 and 3.76 µg MEK inhibitor, as previous 
studies suggested these doses would be within the therapeutic range. The encapsulated MEK 
inhibitor was suspended in PBS and ultrasonicated before being transferred to the 
polyglycidol/BMP2 mixture and diluted with PBS to achieve the 0.46 g/mL polyglycidol 
concentration. Once injected, the polyglycidol should protect and mediate the release of the 
BMP2 and at the same time, MEK inhibitor will be released due to diffusion and degradation of 
the nanoparticle.  
 
In vivo analysis of bone healing following fractures and treatment  
Mid-tibia fractures were performed on Nf1osx
-/-
 mice hours before injection of treatment 
group, and a second treatment injection was performed 7 days later. After 21 days, the mice were 
sacrificed, and the bones were collected for analysis. Wild-type mice were used as a control 
group, and treatment groups included vehicle (unloaded nanoparticle in the polyglycidol matrix), 
BMP2 (mixed with polyglycidol), GSK (MEK inhibitor encapsulated within nanoparticle and 
mixed in polyglycidol matrix), and BMP2+GSK (encapsulated MEK inhibitor mixed with 
polyglycidol matrix and BMP2). 20 µL injections were used as this was the maximum injection 
volume at the fracture site without spillage. Wild-type mice were expected to develop significant 
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and strong callus formation after 21 days of fracture compared to the Nf1 lacking mice that were 
expected to develop very little callus without successful treatment. 
 
 
 
X-ray analysis of the fracture at day 0 and day 21 for each treatment group is shown in 
Figure V-3. In all cases, a fracture can be seen at day 0 with no callus formation. However, the 
wild-type control has a significant callus formation at the fracture site after 21 days which is 
indicative of normal, healthy bone healing process. This effect is absent in the Nf1osx
-/-
 mice with 
vehicle treatment, and little to no callus formation is seen in either one of the single treatment 
groups (BMP2 or GSK). Rather, only the dual drug delivery treatment group achieved significant 
callus formation indicating an enhanced bone healing response to fractures, comparable to what 
is seen in healthy wild-type mice.  
 
Figure V-2. Experimental design for treating fractures in vivo. 
Fracture Injection 1 Injection 2
Bone 
Analysis
Days post-
fracture: 70 21
Tissue Collection
WT
Nf1osx
-/-
Vehicle BMP2 GSK BMP2+GSK 
Treatment groups:
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These results were further validated via microCT scanning of the callus and performing 
quantitative analyses. MicroCT scan of the callus of each treatment group after 21 days is shown  
in Figure V-4A. The WT vehicle treatment group responded as expected, resulting in dense, 
healthy callus formation. Comparably, the vehicle and single treatment groups of the Nf1osx
-/-
 
mice formed callus that appears much less dense. Rather, only the combination treatment group 
achieved healthy and dense callus formation similarly seen in the wild type control. Mineral 
density (such as calcium) is a quantitative measurement that represents an estimate of bone 
strength. The vehicle and single treatment groups of Nf1osx
-/-
 mice had lower mineral density 
 
Figure V-3. X-ray analysis of fracture at days 0 and 21 for all treatment groups. Red circles 
indicate noticeable callus formation. Analysis and figure provided by Dr. Jean of Elefteriou 
Lab, Vanderbilt University. 
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compared to wild-type, but the combination treatment group had significantly greater mineral 
density compared to the single treatment groups, indicating enhanced bone strength. Callus total 
volume was measured to provide a volume of the callus formed after 21 days, and total callus 
bone volume was measured as well to indicate how much of the callus volume consisted of 
actual bone. In both cases, only the dual drug delivery treatment group had significantly greater 
response compared to BMP2 or GSK alone and was comparable to the wild-type response.  
 
 
 
Although callus and bone formation are necessary for the healing process following a 
fracture, bone strength is equally as important as bone volume. Figure V-5 shows the callus peak 
force and callus stiffness analysis, both of which are used to indicate bone strength. In both 
analyses, only the BMP2+GSK treatment group achieved significant bone strength during the 
 
Figure V-4. A: microCT analysis of callus after 21 days of treatment. B: total mineral density 
of callus after 21 days of treatment. C: total callus volume. D: total callus bone volume 
Analysis and figure provided by Dr. Jean Ndong of Elefteriou Lab, Vanderbilt University. 
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experiment and is comparable to the wild-type response. In contrast, neither BMP2 nor GSK 
alone achieved significant bone strength during the 21 day experiment.  
 
 
 
Conclusion 
In summary, this study confirmed the early differentiation defect typical of Nf1-deficient 
osteoprogenitors revealed a block in BMP2 response as a cause of their impaired differentiation 
and led to preclinical data supporting the efficacy of a novel targeted approach to promote bone 
healing in individuals with NF1 pseudoarthrosis, based on the use of MEK inhibition and an 
osteogenic stimulus in the form of BMP2. We can conclude from these analyses that neither 
BMP2 nor GSK can act alone to lead to successful bone healing following a fracture in Nf1Osx
-/- 
mice. Instead, the administration of both drugs simultaneously allowed by the unique dual drug 
delivery formulation resulted in not only for a high volume of callus and bone but also strong, 
healthy bone tissue. The MEK inhibitor used (Trametinib) is already FDA-approved for the 
treatment of patients with unresectable or metastatic melanoma with BRAF
V600E
 or BRAF
V600K
 
 
Figure V-5. Left: Callus peak force analysis of tibia after 21 days of treatment. Right: Callus 
stiffness analysis of tibia. Analysis and figure provided by Dr. Jean Ndong of Elefteriou Lab, 
Vanderbilt University. 
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mutations. Hence, transition for use in the NF1 setting could be accelerated compared to other 
drugs.
24, 25
 This drug delivery formulation potentially could be used for various other 
combination therapy approaches that involve protein or peptide therapeutics. 
 
Experimental 
Polyester nanoparticle synthesis (NP) 
Poly(α-allyl-valerolactone, valerolactone)26 containing 4% allyl functionality was epoxidized 
with meta-chloroperoxybenzoic acid (mcpba, 1.2 eq per alkene, Sigma) in CH2Cl2 (0.065 M 
alkene) for 48 hours and washed with saturated sodium bicarbonate. Resulting polymer was 
dried under reduced pressure. 2,2’-ethylenedioxy-bis(ethylamine) (7.5 µL, 0.51 mmol, Sigma) 
was added to a solution of poly(epoxide-valerolactone, valerolactone) (0.173 g, Mn = 3,644 Da) 
dissolved in CH2Cl2 (21.1 mL). The reaction mixture refluxed at 12 hours at 46° C. Residual 
bisamine was removed by dialyzing with Snakeskin Pleated Dialysis Tubing (MWCO = 10,000) 
against CH2Cl2 to yield nanoparticles (NP).  
 
MEK inhibitor encapsulation into nanoparticles (NP-MEK) 
A solution of nanoparticle (23.0 mg) and MEK inhibitor (5.0 mg, GlaxoSmithKline) in DMSO 
(1.00 mL) was added drop-wise to a vortexing solution of aqueous 1% d-α-tocopherol 
polyethyleneglycol (1000) succinate (Vit E-TPGS (Sigma), 14.0 mL). The resulting precipitation 
was washed by three cycles of centrifugation at 7830 rpm for 20 minutes and replacing the 
supernatant each time with fresh deionized water. The precipitation was freeze-dried to yield a 
white powder (6.4% MEK inhibitor wt/wt determined by NanoDrop UV-Vis at 258 nm, NP-
MEK). 
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Polyglycidol-NP-MEK dual drug delivery system for MEK inhibitor and BMP2 
Polyglycidol homopolymer
23
 was synthesized by first stirring 3-methyl-1-butanol (0.98 mL, 1.7 
M in anhydrous THF) with Sn(OTf)2 (1.28 mL, 0.037 M in anhydrous THF) in a nitrogen-purged 
flask. Glycidol monomer (10.0g, 135 mmol, Sigma) was added drop-wise to the cooled reaction 
mixture. After the monomer addition was complete, the reaction vessel was allowed to warm up 
to room temperature. Once stirring was completely impeded, the crude viscous polymer product 
was dissolved in a minimal amount of methanol and precipitated into vigorously stirring acetone, 
which was then decanted to afford the pure glycidol homopolymer product as a translucent, 
viscous material. BMP2 (Creative BioMart) suspended in 20 mM acetic acid (10 mg/mL) and 
was added to polyglycidol and diluted with PBS for a BMP2 concentration of 0.50 µg/µL and 
polyglycidol concentration of 0.46 g/mL. For MEK inhibitor injections and combo injections, 
encapsulated MEK inhibitor was first sonicated in PBS and transferred to the polyglycidol mix to 
yield a MEK inhibitor concentration of 0.188 µg/µL. Vehicle was prepared using unloaded 
nanoparticles and formulated similarly as described above.  
 
Animals 
All procedures were approved by the Institutional Animal Care and Use Committee (IACUC) at 
Vanderbilt University Medical Center. WT and Nf1osx
-/-
 were generated by crossing Nf1
flox/flox
 
mice and Nf1
flox/flox
; Osx-tTA,tetO-cre mice (Nf1osx
-/-
). To repress transactivation of Cre by the 
Osx promoter during development, 200µg/ml doxycycline was given to pregnant mothers and 
pups in drinking water and refreshed every 2-3 days, as indicated in the text. All experimental 
mice were originated from the same colony to increase genetic homogeneity. Closed mid-
diaphyseal fracture of the tibia was created by three-point bending with an Einhorn device in 2 
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months-old mice, as previously described 
25
. To produce stabilized fractures, an intramedullary 
fixation was used by inserting a 0.25 mm metal insect pin in the tibial tuberosity through the 
patellar tendon, prior to the creation of the fracture. Buprenorphine was administered 
subcutaneously for pain control. Males and females were used. X-rays were taken following 
fracture to exclude any mice with unsatisfactory fractures. All mice handling, bone analyses, and 
statistical analysis were performed by Dr. Jean Ndong of the Elefteriou Laboratory at Vanderbilt 
University. 
 
X-ray and µCT analyses.  
Radiographs were obtained using a digital cabinet X-ray system (LX-60, Faxitron X-Ray, USA). 
CT analyses were performed using a Scanco CT 40 system (Scanco Medical, Bassersdorf, 
Switzerland). Tomographic images were acquired at 55 kVp and 145 mA with an isotropic voxel 
size of 12 m and at an integration time of 250ms with 500 projections collected per 180° 
rotation. 
 
Biomechanical testing 
The fractured tibia from WT and Nf1Osx
-/-
 mice was cleaned of soft tissue and stored frozen in 
PBS until thawed for testing. Three-point-bending was accomplished in displacement control on 
an Instron Dynamight 4481 servo-hydraulic material testing apparatus (Instron, Norwood, MA). 
Hydrated samples were tested with span of 6mm at a rate of 3mm/min.
27
 Force was measured 
using a 100N load cell, and displacement was measured by a linear variable differential 
transformer. Structural properties were extracted from force-displacement curves by custom 
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Matlab algorithms (Mathworks, Natick, MA). Material properties were calculated by accounting 
for structure by utilizing cross-sectional area and moment of inertia as measured by CT. 
 
Statistical analysis.  
A one-way analysis of variance (ANOVA) was used to determine whether differences existed in 
CT -, Raman-, and biomechanical-derived properties among experimental groups. In the event 
that standard deviations were significantly different, the ANOVA was done by the non-
parametirc Kruskal-Wallis test. When differences existed at p<0.05, post-hoc, pair-wise 
comparisons were tested for significance in which the p-value was adjusted (padj<0.05) by Holm-
Sidak's method or Dunn's method (non-parametric). Statistical analysis was performed using 
GraphPad PRISM (v6.0a, La Jolla, CA). Data are provided as mean +/- SD. 
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CHAPTER VI 
 
POST-MODIFICATION REACTIONS: ASSESSMENT OF NANOSPONGES FOR 
TARGETED DRUG DELIVERY 
 
Introduction 
 Despite significant advancements in drug discovery and the development of many 
promising therapeutics, numerous diseases such as cancer remain difficult to treat. The discovery 
of siRNA and the burgeoning field of gene therapy potentially marked the end of even the most 
severe and rare diseases. Although these promising therapies work well in vitro, significant 
obstacles arose when translating to animal models and humans. One of the biggest obstacles is 
delivering the therapeutics to a specific site of action. For example, cancer therapeutics affect 
healthy cells as well as cancerous cells which results in side effects such as neutropenia and 
myelosuppression.
1
 Ideally, the cancer drugs would attack only the tumor cells having no effect 
on healthy cells. Therefore, a need still exists to develop advanced targeted drug delivery 
technologies to overcome these obstacles.  
 In the case of cancer treatment, most drug delivery strategies target cell surface receptors 
that are commonly upregulated in numerous cell types.
2
 Many common receptors have been 
targeted including transferrin
3,
 
4
, EGFR
5
, and folate
6
. Ligands with high specificity for these 
receptors have been identified and attached to nanoparticle surfaces to act as targeted drug 
delivery vehicles as well as diagnostic markers for cell progression.
7
 Integrin receptors have also 
been identified to be highly upregulated in tumor cells
8,
 
9
, and RGD containing peptide 
sequences have been used as targeting agents to help treat tumors since they bind with high 
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affinity for integrin receptors.
10
 In this work, we investigated the potential of our developed, 
multifunctional nanosponges to attach targeting peptides and imaging dyes for cell surface 
targeting of cancer cells. The nanosponge is an excellent platform vehicle for this purpose due to 
the pendant functionalities that can undergo post-modification reactions. For example, accessible 
alkene groups from the nanoparticle surface can be utilized to undergo thiolene click reactions 
with thiol-containing targeting ligands to form covalent bonds. 
The loss of pancreatic beta cells is a major hallmark of type 1 diabetes, and despite its 
worldwide prevalence, much is still unknown regarding its pathology. Therefore, the ability to 
noninvasively quantitate beta cell mass and directly target therapeutic cargo to these cells are 
paramount to enable a greater understanding of diabetes pathology, provide a diagnostic marker 
for both type 1 and type 2 diabetes, and help develop current and new therapeutic approaches. 
Pancreas transplants and islet cell transplantation are available medical options, but it is difficult 
to quantitatively measure the number of surviving islets after transplantation. Currently, 
radiolabels can be used to quantitate biomarkers of beta cells, but this only indirectly reflects 
beta cell mass and does not determine whether the beta cell mass is increasing or decreasing.
11
 
Other imaging agents have been investigated as well including glucose analogs
12
 and 
antibodies
13
 but have failed to provide an accurate quantitative measure of beta cells. Pancreatic 
islet cell mass can be measured histologically, but this requires surgical removal of the 
pancreas.
14
 Therefore, a major medical goal is to develop a method to measure the increase and 
decrease of beta cell mass over time and indicate the appropriate time course to intervene if 
necessary. Currently, there is no way to successfully target islet cell receptors with high 
specificity that would allow accurate quantification of beta cells or allow a targeted drug delivery 
approach.  
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A targeted, dye-labeled nanoparticle could potentially act as a way to image and 
quantitate beta cells in the pancreas as well as allow the potential for drug delivery to these 
specific cells to treat type 1 or type 2 diabetes. An ideal vehicle to image or deliver therapeutic 
cargo directly to the beta cells in Islets of Langerhans would be non-toxic and biodegradable, 
allow flexible payloads for delivery of a wide range of drugs, possess targeting capabilities 
specifically to the islet surface, and have high-affinity to the islets with minimal off target 
effects. As previously demonstrated, the polyester nanosponge is a biodegradable platform 
delivery vehicle that is capable of encapsulating and releasing drugs and also possesses pendant 
functionalities on the particle surface for post-modification reactions such as attaching targeting 
moieties. The major advantages of the nanosponge include: tailored nanoscopic size, adjustable 
crosslinking density to control drug release at a defined release rate, conjugation of various 
targeting ligands via thiolene click reactions, and attachment of reporter dyes via NHS-ester 
chemistry or hydrazide-aldehyde orthogonal chemistry. 
Exendin-4 (also known as exenatide) is an agonist for the glucagon-like peptide-1 
receptor
15
 and has been shown to be an effective treatment for diabetes patients.
16
 Its high 
affinity for the GLP1 receptor makes it an attractive targeting ligand for beta cells in the Islets of 
Langerhans. Compared to antibodies, peptides are much easier to handle, less sensitive, and 
easier to analyze in regards to organic modification reactions such as conjugation to a 
nanoparticle surface. Exendin-4 is commercially available and can be synthesized with a cysteine 
amino acid on the N-terminus that would allow for thiolene click reactions with alkenes without 
affecting peptide activity. Therefore, a nanoparticle with pendant exendin-4 peptides and 
imaging dyes could potentially act as diagnostic tools to accurately measure beta cell mass 
within the pancreas. Additionally, targeted nanoparticles have the potential to be loaded with 
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various drugs for the direct treatment of cells in the pancreas. In this work, we investigated 
orthogonal chemistries to attach exendin-4 and imaging dyes to the surface of nanoparticles to 
act as targeted vehicles to cells expressing GLP1 receptor, particularly pancreatic islet cells.  
 
Results and Conclusions 
 The introduced functionalities of the nanoparticles are utilized for post-modification 
reactions including targeting peptide attachments and dye attachments. Multi-step orthogonal 
chemistry approaches were developed in order to eliminate side reactions that could potentially 
interfere with the structure or activity of the biologically active targeting peptides. For cancer 
cell targeting strategies, a cRGD peptide was covalently linked to the nanoparticle surface 
followed by a dye attachment step which was then incubated with HeLa cells and imaged for 
cell-surface localization.  For pancreatic islet cell targeting strategies, cysteine-modified exendin-
4 was attached to the nanoparticle surface followed by dye attachment using orthogonal 
aldehyde-hydrazine chemistry. 
 
 
 
 
Figure VI-1. Attachment of cRGD peptide to nanoparticle surface via thiolene click. 
Thiol-ene Click Tumor targeting 
nanosponge
(αv β3 integrin receptor)
Polyester
Nanosponge
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Attachment of cRGD peptide and imaging dye to nanoparticle surface via thiolene click 
and NHS-ester chemistries 
  
 The pendant functionalities of the nanosponge and its solubility in organics allow for 
simple post-modification reactions. Polyester nanosponges can be synthesized to contain a 
defined number of alkene groups which can then be utilized for reactions such as thiolene click. 
In this study, 100 nm nanoparticles containing 4% avl and 7% crosslinking density were reacted 
with thiol-functionalized cRGD peptide using UV and 2,2-dimethoxy-2-phenylacetophenone as a 
photoinitiator. The success of the reaction can be analyzed with 
1
H NMR by observing the slight 
reduction of the alkene peaks at 5.0 ppm and 5.7 ppm as well as the emergence of the peptide 
peaks at  4.4-4.7 ppm and 7.2 ppm of the purified product (Figure VI-2).  
 
 
 
 Since the nanoparticle synthesis uses an excess of bis(amine) crosslinker, free amines 
remain that can also be utilized for post-modification reactions. In order to determine targeting 
 
Figure VI-2. 
1
H NMR spectra of cRGD peptide (bottom), polyester nanosponge (middle), and 
purified sample of nanoparticle with cRGD attached (top). 
cRGD
Polyester Nanosponge
cRGD-
Nanosponge
Attached Peptide
95 
 
capabilities of the cRGD-modified nanoparticle, an imaging dye attached to the nanoparticle is 
required. Simple and efficient NHS-ester chemistry was employed to react an NHS-ester 
AlexaFluor dye with the primary amines of the nanoparticle to form an amide.  
 
In vitro imaging of fluorescent, targeted nanoparticles in HeLa cells 
 HeLa cells were chosen to test the targeting capabilities of the cRGD-nanoparticles due 
to their overexpression of integrin receptors.
17
 Fluorescently-labeled, targeted nanoparticles were 
added to HeLa cells and imaged with confocal microscopy, and cell surface attachment was seen 
within two hours of incubation which is comparable to other nanovehicles using similar targeting 
strategies.
18,
 
19
 No cell surface or cell uptake was seen in a non-targeted nanoparticle control 
group after 2 hours. This suggests that improved cancer cell targeting is due to the cRGD 
attachment to the nanoparticle surface as expected. 
 
 
Figure VI-3. Confocal microscopy (63x magnification) of HeLa cells treated with 
AlexaFluor488 labeled, cRGD-nanosponges for two hours at a nanoparticle concentration of 
70 µg/mL. 
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Orthogonal chemistries for sequential exendin-4 and dye attachment to nanoparticle 
surface 
 
 Biologically active targeting moieties are often sensitive to organic chemistry reactions 
and functionalized dye attachment is not always specific. For example, NHS-ester dyes can be 
used to attach dyes to particles that have pendant free amine groups; however, targeting peptides 
typically have at least one amine in the peptide structure which can potentially react with the 
dye. Therefore, orthogonal chemistry approaches must be carefully designed in order to 
successfully attach both targeting ligands and reporter dyes to the nanoparticle surface without 
side reactions. A combination of hydrazide-aldehyde and thiolene click reactions was employed 
to sequentially attach peptide and reporter dye to the surface of the nanoparticle (Figure VI-4).  
 
 
 
 
Figure VI-4. Reaction scheme to orthogonally attach Cys40-EX4 peptide and AlexaFluor dye to 
the nanoparticle. 
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 In the first step, N-succinimidyl-p-formylbenzoate was reacted with a 100 nm 
nanoparticle containing 5% avl and 5% crosslinking density via NHS-ester chemistry overnight 
in DMSO and purified by dialysis. 
1
H NMR showed the presence of aromatic peaks as well as 
aldehyde peaks from the aldehyde linker at 8.1-8.3 and 10.2 ppm, respectively. A cysteine-40 
modified exendin-4 (Cys40-EX4) was added to this product along with 2,2-dimethoxy-2-
phenylacetophenone to act as a photoinitiator, and this mixture was irradiated at 365 nm for 24 
hours in deuterated DMSO. Deuterated solvent was used in order to easily analyze the reduction 
of alkenes via 
1
H NMR without having to perform a purification step to remove the DMSO. The 
marked reduction of the allyl peaks as seen in Figure VI-5 indicates the success of the covalent 
attachment between the thiol and allyl group. Additionally, a significant retention time shift of 
the peptide was seen in the HPLC chromatograph after attachment to the nanoparticle surface 
which supports the success of the thiolene click reaction (Figure VI-6).  
 
 
 
 
Figure VI-5. 
1
H NMR spectra of nanosponge before and after exendin-4 peptide attachment.  
Nanosponge
EX-4 Nanosponge
Allyl peaks reducedPeptide 
peaks
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In the final step, the hydrazide functionalized dye (iFluor750) as added to the EX-4 
modified nanoparticles in DMSO and allowed to stir overnight. The hydrazide reacts directly 
with the aldehyde to form a hydrazone. This type of reaction is commonly found in protein 
conjugation kits that react well between pH 5 and pH 7. The final product was dialyzed to 
remove any potential free peptide as well as any unreacted dye.  
 
 
 
GLP1 receptor activation from EX-4 modified nanosponges 
 In order to confirm that exendin-4 activity was preserved after nanoparticle attachment, 
cAMP levels were measured in HEK 293 cells expressing GLP1R after treatment with the cys40-
modified exendin-4 peptide, EX-4 modified nanoparticles (EX4-NP), and non-targeted 
nanoparticles (NP) and forskalin was used as a positive control (Figure VI-7). In this preliminary 
study, 1 µM of cys40-exendin-4 resulted in a 20-fold change of cAMP compared to basal levels 
as expected since exendin-4 activation of GLP1R increases cAMP. Similar cAMP levels were 
 
Figure VI-6. HPLC chromatograph of peptide (top) and nanoparticle after peptide 
attachment (bottom). 
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achieved using the exendin-4 modified nanosponges (equivalent to 1 µM EX-4) indicating that 
exendin-4 activity is preserved even after attachment to the nanoparticle surface. Since 0.1 µM 
of EX4-NP also achieved a 20-fold change of cAMP levels, it’s apparent that the cAMP response 
is not dose-dependent at these concentrations, and saturation has likely occurred. Therefore, 
lower concentrations should be utilized in future studies to achieve a dose-response curve that 
will better indicate if any exendin-4 activity is impacted due to nanoparticle attachment. 
Nevertheless, this preliminary experiment suggests that the exendin-4 modified nanosponges 
successfully bind and activate GLP1R and can be utilized as potential targeted drug delivery 
vehicles to cells expressing GLP1R, particularly the beta cells in the pancreatic islets.   
 
 
 
 
Figure VI-7. Measurement of cAMP levels in 293 cells after treatment with exendin-4, 
exendin-4 modified nanoparticles, and nanoparticle alone. Experiment and data were 
produced by Dr. Neil Phillips of the Al Powers Lab. 
EX-4 EX4-NP NP
EX-4: cysteine modified exendin-4
EX4-NP: EX-4 targeted nanoparticle
NP: non-targeted nanoparticle
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Biodistribution of EX-4 modified nanosponges in vivo 
 In order to test EX-4 modified nanosponges’ ability to preferentially locate to GLP1R 
expressing cells, in vivo experiments must be undertaken. Although the ultimate goal is to 
specifically target the islet cells in the pancreas, an easier and more practical proof-of-concept 
experiment is to first target ectopic tumors from a cell line that over-expresses GLP1R. Tumors 
that over-express the GLP1 receptor will be grown in the hind legs of mice, and fluorescently 
labeled, targeted nanoparticles will be administered systemically. As a control, a separate set of 
mice will grow tumors from a similar cell line that does not express GLP1R. 
 The mice will undergo near infrared imaging at various time points. If successful, 
targeted nanosponges will preferentially locate to the GLP1R-expressing tumor over time 
whereas the nanosponges should be cleared from the mice containing the tumors that don’t 
express GLP1R. The mice handling and imaging will be performed by Dr. Neil Phillips of the Al 
Powers Laboratory at Vanderbilt University. 
 
Conclusion 
Post-modification reactions were successfully utilized to attach targeting peptides and 
imaging dyes to the surface of nanoparticles for both cancer and diabetes applications. The 
attachment of cRGD peptides to the nanoparticle surface resulted in the cell surface localization 
of the nanoparticles in cancer cells. Therefore, this targeted drug delivery system could 
potentially act as a useful strategy to deliver chemotherapeutics directly to the tumor.  
For the purpose of pancreatic islet cell targeting, a cysteine modified EX-4 was 
successfully attached to the nanoparticle using thiolene click chemistry. A unique aldehyde-
hydrazide chemistry was employed to attach dyes to the surface of the nanosponge without 
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affecting the peptide. Preliminary experiments showed EX-4 activity was preserved despite 
nanosponge attachment and therefore can act as a targeting ligand for beta cells in pancreatic 
islets. The further development of this targeted delivery system could have major implications 
for the treatment of type 1 diabetes. 
 
Experimental 
Materials 
Cyclic-RGD peptide was obtained from Peptides International and used as received. Cysteine-40 
modified exendin-4 was obtained from Chem-Impex International and used as received. 
Alexafluor488 was received from Life Technologies and iFluor750 was acquired from AAT 
Bioquest.  N-succinimidyl-p-formylbenzoate was purchased from Santa Cruz Biotechnology and 
used as received. Snakeskin pleated dialysis tubing was purchased from Thermo Scientific. 
DMEM was purchased from Gibco by Life Sciences and supplemented with 10% fetal bovine 
serum and 5% antibiotic-antimycotic. All other materials were obtained from Sigma Aldrich or 
Gibco by Life Technologies and used as received. 
 
Characterization 
1
H NMR spectra were obtained from a Bruker AC400 Fourier Transform Spectrometer with 
CDCl3/TMS as solvent. High-performance liquid chromatography (HPLC) was carried out using 
a Waters chromatograph equipped with a Waters 2996 variable wavelength photodiode array 
detector, a Waters 1525 binary HPLC pump, and a reverse phase column (100 x 4.6 mm i.d., 
pore size 5 μm, Thermo Scientific). All runs were performed using an isocratic gradient of water 
and acetonitrile (1:1 v/v) at a flow rate of 1 mL/min. Confocal microscopy was performed using 
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a Zeiss Inverted LSM 510 Meta laser scanning confocal microscope, equipped with an argon 
laser, a 543 nm HeNe laser, a Plan-Neofluar 40x/1.3 oil lens and a Plan-Apochromat 63x/1.4 oil 
lens.  
 
Synthesis of cRGD functionalized nanoparticle (cRGD-NP) 
100 nm nanoparticles containing 7% epoxide and 4% allyl were synthesized as reported 
previously. In a nitrogen-purged 1-dram vial, nanoparticle (20 mg, Mw per alkene = 1408.5 
g/mole, 1.42x10
-5
 moles alkene) was dissolved in a minimal amount of anhydrous, degassed 
DMSO (~0.100 mL). Cyclic RGD peptide (3.1 mg, Mw = 578.27 g/mole, 0.38 eq with respect to 
alkene, 5.33x10
-6
 moles) and 2,2-dimethoxy-2-phenylacetophenone (0.728 mg, 0.2 eq with 
respect to alkene, 2.84x10
-6
 moles) in minimal amount of DMSO were added to the nanoparticle 
solution and allowed to stir at 37 °C under UV lamp (365 nm) for 48 hours. Product was purified 
by dialyzing in Snakeskin Pleated Dialysis tubing (MWCO = 10,000 Da) against 
acetonitrile:methanol (50:50).  
 
AlexaFluor488 dye attachment to cRGD-NP (cRGD-NP-488) and nontargeted 
nanoparticles (NP-488) 
 
In a nitrogen-purged 1-dram vial, cRGD-NP (4.0 mg) was dissolved in DMSO (0.200 mL). 
AlexFluor488 (51.5 µL, 5 mg/mL stock in DMSO) was added to the vial using a microsyringe, 
the vial was covered in foil to protect from light, and the reaction was allowed to stir for 24 hours 
at room temperature. Product was purified by dialyzing in Snakeskin Pleated Dialysis tubing 
(MWCO = 10,000 Da) against acetonitrile: methanol (50:50). To form a non-targeted, 
fluorescent nanoparticle, the same reaction was performed except using nanoparticles without 
cRGD attached. 
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Confocal microscopy 
HeLa cells were plated on uncoated 14 mm Microwell (MatTek) dishes at a density of 3 x 10
5
 
cells in medium. On the day of experiments, cells were washed three times with PBS and then 
incubated with phenol red free, high glucose DMEM containing 70 µg/mL of either cRGD-NP-
488, NP-488, or unlabeled nanoparticle as a negative control  for 2 hours at 37 °C in a 5% CO2 
environment. The cells were then washed four times with PBS to remove nanoparticles that did 
not undergo cell uptake or cell surface attachment, and 0.5 mL Opti-MEM was added for 
imaging. 
 
Synthesis of aldehyde functionalized nanoparticle via NHS-ester chemistry 
Nanoparticles (36.9 mg, 0.246 µmols) were added to a flame-dried, argon-purged 1-dram vial 
and dissolved in a minimal amount of anhydrous DMSO. N-succinimidyl-p-formylbenzoate (58 
µL, 0.127 M in DMSO) was added and allowed to stir for 24 hours. The reaction was dialyzed 
with Snakeskin pleated dialysis tubing (MWCO = 10,000 g/mol) against dichloromethane. 
1
H 
NMR confirmed presence of aromatic protons at 8.1-8.3 ppm and aldehyde protons at 10.2 ppm.  
 
Sequential attachment of exendin-4 peptide via thiolene click chemistry and dye 
attachment via hydrazide chemistry 
 
In a 1-dram vial, aldehyde-functionalized nanoparticle (15.0 mg, 5.67x10
-6
 moles alkene) was 
dissolved in a minimal amount of deuterated DMSO. Cys40-Exendin-4 peptide (3.9 mg, 
9.00x10
-7
 moles) and 2,2-dimethoxy-2-phenylacetophenone (0.29 mg, 0.2 eq with respect to 
alkene, 1.13x10
-6
 moles) in minimal amount of deuterated DMSO were added to the nanoparticle 
solution and allowed to stir room temperature and exposed to UV (365 nm) for 24 hours. Crude 
1
H NMR confirmed reduction of the allyl peaks and presence of peptide peaks. The crude 
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reaction mixture was used for next step to avoid product loss from an unnecessary purification 
step. EX-4 functionalized nanoparticle was already dissolved in DMSO from the previous 
reaction (15.0 mg, 1x10
-7
 mol). Alexafluor488 dye (0.57 mg from a 5 mg/mL stock solution in 
dmso, 1x10
-6
 mol) was added to the nanoparticles. Reaction stirred for 24 hours in darkness 
followed by dialysis against methanol/acetonitrile (50:50). 
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CHAPTER VII 
 
POLYCARBONATE HYDROGELS WITH TUNABLE SWELLING AND DRUG RELEASE 
 
Introduction 
Polymeric networks continue to be essential in the development of hydrogel materials for 
advanced biomedical applications.1, 2, 3 These polymer networks are versatile and increasingly 
important materials due to their tunable network composition that can be reconfigured in 
simultaneous network forming and deforming processes. Such materials have helped make 
significant improvements in the area of tissue engineering in segmenting biological and synthetic 
structures and in the area of re-shapeable glass like polymers called vitrimers. Much effort has 
been devoted towards acrylate based materials as they are biocompatible and hydrophilic with 
the ability to swell, protect, and release their cargo.4, 5 One of the hallmarks of hydrogels is the 
ability to absorb large amounts of water and swell many times its own weight.6 For years, 
researchers have developed smart, or stimuli-responsive, materials in which the chemical or 
mechanical properties of the hydrogel can change depending on temperature, pH, magnetic field, 
and solvent.7, 8, 9, 10  However, degradability of these materials has been an obstacle since 
functionalized linear acrylates and multi-arm-PEG structures are the two main components that 
have pioneered the field on hydrogels to react under mild and fast reaction conditions such as 
thiolene click reactions.  
Current research in the field is devoted to include degradable components and to 
investigate stimuli free reactions such as amine-oxime reactions in addition to other click 
reactions.11 Although hydrogels have been demonstrated to act as useful vehicles for drug 
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delivery applications12, 13, 14, 15, 16, one of the major limitations is the rapid release of the 
therapeutic.6 Therefore, advanced hydrogel materials are required to overcome the limitation of 
rapid drug release in order to allow slower, adjustable drug release rates that can satisfy various 
medical needs. Although the hydrophobicity of degradable materials such as polyesters and 
polycarbonates offer some challenge if a high swellability of the material is anticipated, 
hydrophobic small molecules have a higher residence time in hydrophobic materials as opposed 
to hydrophilic materials in which a rapid release of therapeutics is a common problem.  
To improve the rate of drug release and swellabilities in hydrogels, a balance between 
crosslinking density, hydrophilicity, and hydrophobic components must be accomplished. In this 
work, we sought to improve and further tune the swellabililty and hydrophilicity by introducing a 
three component system consisting of a linear polycarbonate, a linear dithiol ethylene oxide unit, 
and a novel semi-branched polyglycidol with a high number of reactive –OH groups, a branched 
PEG mimic. Recently discovered semi-branched polyglycidols maintain a lower branching 
compared to hyper-branched materials but resemble a shorter overall structure and more 
compatible version to higher molecular PEG units. This molecule is hydrophilic due to the large 
number of pendant hydroxyls which is thought to enhance the hydrophilicity of a gel when 
introduced within the gel network. Polycarbonates are one of the most well-known degradable 
polymers, and the improvement of synthetic procedures such as organo-catalyzed and metal 
catalyzed reactions enabled the integration of polycarbonates into complex materials. For 
example, intermolecular crosslinking with difunctionalized short PEG diamines and disulfides 
facilitated nanoparticles in a variety of selected sizes which consist of nanonetworks from 
hydrophilic and hydrophobic components.
17
 This same concept of polymer crosslinking is 
translated to the development of three component hydrogels to form improved hydrogels that 
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include semibranched polyglycidol component. The polyglycidol does not participate the 
crosslinking reaction but rather acts as a “filler” in the network to influence the swelling and to 
control the drug release. However, the OH-functional groups of the polyglycidol can be made 
part of the hydrogel network through transesterification reactions in the presence of Zn(OAc)2 to 
reconfigure the network. In this work, we synthesized and studied the influence of the width of 
the network maintained by the difunctional crosslinker and the introduction of the semibranched 
polyglycidol on swelling and drug release.  
 
Results and Discussion 
We report the synthesis polycarbonate based hydrogels that contain semi-branched 
polyglycidols entrapped into the polycarbonate-diethylene oxide matrix. The primary OH groups 
of the polyglycidol can react in a transesterification reaction to form reconfigurable crosslinked 
materials. We first synthesized allyl functionalized linear polycarbonates with Sn(OTf)2 as 
catalyst and isoamyl alcohol as initiator. In a reaction with dithiol ethylene oxides, a crosslinked 
network was formed via thiolene click reactions in the presence or absence of semi-branched 
polyglycidols. The resulting two hydrogel materials were characterized via water swelling 
capabilities and degradation in phosphate buffered saline.  Additionally, these gels could be 
formed in the presence of drugs thereby entrapping the drug within the network in a non-
covalent manner. Paclitaxel was chosen as a model drug to study the drug release from these two 
carriers and was incorporated during the crosslinking reaction. The presence of the polyglycidol 
as well as the length of the dithiol crosslinker influenced the swelling capabilities and were 
responsible for a varied drug release behavior. Additionally, the present polyglycidol can be 
covalently attached to the network in a transesterification reaction with Zn(OAc)2. The 
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reconfigurable nature of the transesterification reactions leads to novel materials which are 
tougher than the comparable hydrogels which only carry the entrapped semi-branched 
polyglycidols. The present work introduces and compares the effects of polyglycidols as 
components into polycarbonate crosslinked materials that are either present or absent in order to 
shape the physicochemical properties of hydrogels used as drug delivery materials. 
 
Thiolene click model reaction 
Allyl-functionalized polycarbonate was synthesized as previously reported.18 To 
demonstrate the efficacy of the click reaction, dithiol crosslinker was added to a solution of 
poly(MAC, MEC) (1 thiol per alkene) and DMPA (0.2 equivalents per alkene) in DMSO-d6 at a 
concentration of 0.21 M and irradiated with UV light for 5 minutes. The sample was then 
immediately analyzed by 1H NMR which indicated greater than 95% conversion based on the 
reduction of the alkene shifts at 5.87 ppm and 5.20 ppm. Therefore, the thiolene click reaction is 
rapid and successful, even at dilute concentrations. The model reaction was completed using 
dilute conditions since concentrated conditions result in the formation of hydrogel materials 
which are insoluble in solvent and cannot be analyzed by NMR. 
 
Hydrogel Synthesis  
Hydrogels were formed via thiolene click crosslinking of allyl-functionalized carbonate 
copolymers and a dithiol crosslinker. The polycarbonate copolymer was synthesized as reported 
previously.18 The PC and PC-1.5k hydrogels were prepared by reacting the allyl with the short or 
long (1.5k) dithiol crosslinker in DMF with DMPA (0.2 eq per alkene) under UV light (365 nm) 
for 5 minutes. Gels readily formed within minutes and were rinsed with methanol and water to 
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remove unreacted material and residual DMF. Yields were determined by measuring the dried 
mass of the gel compared to the total mass of the precursor reactants, and typical yields were 
greater than 90%.  
 
 
 
In a separate series of gels, water-soluble polyglycidol was added to the precursor mix to 
investigate the change of gel properties due to introducing a hydrophilic component to the 
hydrogel matrix. Additionally, the entrapped polyglycidol can be used for post-modification 
reactions such as transesterification. These gels (PC-PG and PC-1.5k-PG) contained a 1:1 ratio 
of polycarbonate to polyglycidol by mass and were synthesized by reacting the allyl of the 
polycarbonate with the short or long (1.5k) dithiol crosslinker as described previously. The 
polyglycidol did not impede the thiolene reaction and was successfully incorporated into the 
 
Figure VII-1. Synthesis of polycarbonate gels with short or long dithiol crosslinker in the 
presence or absence of polyglycidol. 
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crosslinking network as indicated by the yields (greater than 75%) after soaking and rinsing with 
water and methanol sequentially. To ensure free polyglycidol was effectively washed away, these 
gels were soaked in water before rinsing several times with water and methanol.  
 
Zinc acetate mediated transesterification reaction for gel network reconfiguration 
Zinc acetate has been shown to promote transesterification rearrangements at high 
temperatures.19 Thus, zinc acetate was mixed into the polymer precursor solution before gel 
formation to demonstrate reconfiguration capabilities. After gel formation, the gel was added to a 
120  C oil bath overnight, yielding a physically tougher gel due to the polyglycidol becoming 
covalently attached to the ester side groups of the polycarbonate. Thermogravimetric analysis 
(TGA) was used to characterize the materials before and after the transesterification step. As 
seen in the top TGA curve in Figure VII-2, the polymer materials began to degrade at 270  C. 
Looking at the first-derivative curve (%/ C), two inflection points were seen at around 300  C 
and 400  C which indicate the points of greatest rate of weight change. The two inflection points 
are typical of a mixture which makes sense considering the polycarbonate gel and polyglycidol 
are non-covalently attached. However, a significant change in the TGA curve was seen after 
transesterification. As seen in the bottom TGA curve in Figure VII-2, the change in weight curve 
is more representative of a single-component material. Although two inflection points were still 
seen in the first-derivative curve (%/ C), the greatest rate of weight change occurred at 360  C. 
These findings suggest the material underwent chemical modification during the 
transesterification step. Since transesterification is reversible, it’s likely that not all polyglycidol 
became covalently linked within the network which would account for the first inflection point 
seen at 240  C.  
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Tunable swelling ability of hydrogels 
Although gels made from hydrophilic polymers typically exhibit excellent water sorption 
capabilities20, the hydrogels prepared in this study had low to moderate water sorption ability. As 
expected, water swelling increased with increasing hydrophilicity within the gel network. 
Equilibrium water content at room temperature averaged 20.0% for PC gels, 85.5% for PC-PG 
gels, 179% for PC-1.5k gels, and 211% for PC-1.5k-PG gels, and the swelling ability was not 
 
Figure VII-2. Thermogravimetric analysis of polycarbonate-polyglycidol hydrogel before 
(top) and after zinc acetate catalyzed transesterification (bottom). Analysis and data provided 
by Anand Rahalkar of the Muthukumar laboratory, University of Massachusetts Amherst.  
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sensitive to temperature or pH (Figure VII-3). The low water absorption for PC is expected due 
to the very hydrophobic nature of the polycarbonate backbone. Although the presence of the 
ethylene oxide crosslinker allows for a more hydrophilic environment, it is not enough to 
overcome the hydrophobicity of the polycarbonate unless the PEG crosslinker has a significantly 
greater molecular weight such as with the PC-1.5k gels, which had 9-fold greater swelling values 
compared to the PC gels. Also, the presence of polyglycidol in the network improved water 
swelling significantly, likely due to its hydrophilic nature. By simply adding this hydrophilic 
“filler” to the short crosslinker gels, swelling values increased over 4-fold. It is important to note 
that the recorded dried mass of the gels before and after swelling in water were generally 
consistent with each other, indicating insignificant degradation and loss of material during the 
duration of these swelling experiments. However, PC-PG and PC-1.5k gels lost mass after 
swelling in simulated gastric fluid (SGF), likely due to degradation but also because the gels 
broke into smaller pieces which made it difficult to measure the mass. 
 
 
 
 
Figure VII-3. Swelling ability of each type of gel in water (25 and 37 °C) and simulated 
gastric fluid (pH 1.2). 
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Hydrolytic degradation profiles of hydrogels 
 
 
 
Polycarbonate materials typically degrade hydrolytically at very slow rates21, and 
previous studies indicate the primary method of degradation of these gels is from hydrolysis of 
the ester side-group.22 For in vivo applications, predictable gel degradation is imperative, and a 
tunable degradation would be ideal to meet specific needs of individual biomedical applications. 
Degradation experiments of the prepared gels were conducted under simulated physiological 
conditions (PBS pH 7.4 at 37  C) and monitored by measuring the swelled mass over time. In all 
cases, the gels degraded slowly (Figure VII-4). Interestingly, gels containing the short crosslinker 
had significantly slower degradation rates with PC at 88% and PC-PG at 74% remaining mass 
after 34 days. This is likely due to the overwhelming hydrophobicity of these gels which are less 
likely to attract water for hydrolysis. PC-1.5k-PG gained mass up to day 25 before a loss of mass 
was recorded at day 34. The increase of mass over time can be attributed to the enhanced 
 
Figure VII-4. Degradation profiles of each gel in PBS at 37 °C. 
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swelling ability of the gel as the hydrophilic network of this gel is more exposed to water as the 
ester bonds degrade over time, and this agrees with what is reported with similar gels  using long 
PEG-crossinkers.22 Surprisingly, this trend was not seen for the PC-1.5k gel which had almost 
completed degraded by day 34. 
 
Paclitaxel encapsulation and drug release 
 
 
 
In order to encapsulate paclitaxel into the gel, the drug was mixed with the polymer 
precursors prior to gel formation, and these gels were purified as described previously. The 
solvent rinses were collected and analyzed for non-encapsulated paclitaxel by HPLC. Loading 
efficiency was determined by comparing the amount of non-encapsulated drug with the amount 
initially added to the polymer mix, and in all cases, loading efficiency was very high ( > 98%). 
 
Figure VII-5. Left: Cumulative release of paclitaxel in PBS at 37 °C. Right: Average released 
paclitaxel concentration per day for each gel. 
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PTX-loaded gels were placed in PBS (pH 7.4) at 37  C to monitor the in vitro release rate 
of paclitaxel. In all cases, paclitaxel was released at controlled rates with PC achieving as low as 
7.2% drug release and PC-1.5k-PG achieving as high as 29.9% drug release after 7 days. The 
rate of release is somewhat proportional to the gel’s water swellability as the gels with greater 
swelling ability released paclitaxel at faster rates. This makes sense as more swelling would 
potentially allow faster rates of diffusion of paclitaxel from the gel. The differences in release 
rates may also be attributed to greater pore size within the gel networks. For example, PC-1.5k 
achieved 19.8% drug release after 7 days compared to 7.2% achieved by PC. The use of the 
significantly longer linker (1.5k) greatly enhances the hydrophilicity within the gel network, but 
it also potentially increases pore size within the network as crosslinks will not be as closely-knit 
as seen with the shorter crosslinker in PC. Additionally, polyglycidol played a significant role in 
drug release as seen in the 12.2% drug release after 7 days with the PC-PG gel which is 1.7-fold 
faster than PC. Again, this is attributable to polyglycidol’s ability to enhance hydrophilicity 
within the network, but since polyglycidol acts as an additive, it can potentially affect pore size 
and drug release kinetics as well.23 
PC and PC-PG gels containing paclitaxel were also used to measure drug release in 
simulated gastric fluid (pH 1.2) to determine if these gels could retain their therapeutic cargo in 
acidic conditions for an oral drug delivery route. In both cases, very little paclitaxel (less than 
3%) was released even after 12 hours in the simulated gastric fluid. This suggests that these types 
of gels could potentially be investigated as an oral drug formulation. Also, the ability to 
withstand the acidic conditions of the stomach allows these gel materials to potentially act as 
enteric coating for other drug formulations.  
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Conclusion 
 A series of hydrogels were synthesized and characterized by their water swelling ability, 
degradation profile, and drug release profile. Indeed, allyl-functionalized polycarbonates undergo 
thiolene click reactions with dithiol crosslinkers to form insoluble, gel materials when conditions 
are concentrated. Hydrogels were formed with different sized crosslinkers in the presence or 
absence of a hydrophilic component, polyglycidol. The insertion of a hydrophilic component 
within the gel network caused significant effects on water swelling ability as well as rate of drug 
release. Additionally, increasing the size of the dithiol-PEG crosslinker resulted in similar 
effects. All gels degraded hydrolytically at slow rates and therefore could be used for various 
drug delivery routes including oral and implants. The ability to form a gel in the presence of a 
drug allows the possibility to create novel drug delivery formulations of a therapeutic that 
requires sustained release, and the overall drug release rate can be adjusted by manipulating the 
 
Figure VII-6. Cumulative release of paclitaxel in simulated gastric fluid at 37 °C. 
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hydrophilicity within the gel network.  Therefore, this novel hydrogel material can act as a 
platform delivery formulation to meet the needs of various sustained release applications.  
 
Experimental 
Materials 
Poly(MAC, MEC) and polyglycidols were synthesized as reported previously.
18, 24
 Spectra/Por® 
Dialysis membrane was purchased from Spectrum Laboratories Inc. Phosphate Buffered Saline 
(PBS) was obtained from Gibco by Life Technologies and pH was adjusted to 7.4. Simulated 
gastric fluid (SGF) was prepared by mixing 2.0 g NaCl with 7.0 mL concentrated HCL, diluting 
with water to 1.0 L, and adjusting pH to 1.2. All other chemicals were purchased from Sigma-
Aldrich and used as received 
 
Characterization 
1
H NMR spectra were obtained from a Bruker AC400 Fourier Transform Spectrometer, with 
DMSO-d6 as the solvent. High-performance liquid chromatography (HPLC) was carried out 
using a Waters chromatograph equipped with a Waters 2996 variable wavelength photodiode 
array detector, a Waters 1525 binary HPLC pump, and a reverse phase column (100 x 4.6 mm 
i.d., pore size 5 μm, Thermo Scientific). All runs were performed using an isocratic gradient of 
water and acetonitrile (1:1 v/v) at a flow rate of 1 mL/min. Thermogravimetric analysis (TGA) 
was carried out using an Universal V4.5A TA instrument and heated from 25 °C to 500 °C at a 
rate of 10 °C/min. TGA analysis was conducted and provided by Anand Rahalker of the 
Muthukumar lab at University of Massachusetts Amherst.  
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Synthesis of polycarbonate hydrogel via thiolene click (PC and PC-1.5k) 
3,6-dixoa-1,8-octanedithiol (8.6 uL, 5.2 x 10
-2
 mmol) was added to a solution of poly(MAC, 
MEC) (100 mg, Mn = 4,712 Da, 0.105 mmol alkene) and 2,2-dimethoxy-2-phenylacetophenone 
(DMPA, 0.2 eq per alkene, 5.4 mg) in DMF (100 uL). The solution was UV-irradiated (365 nm) 
for 5 minutes. The resulting gel (PC) was soaked and rinsed sequentially with methanol and 
water to remove unreacted starting material and solvent, and gel was dried via lyophilization. 
Gels containing longer crosslinker (PC-1.5k) were synthesized in the same manner but using 
PEG-dithiol (78.6 mg, Mn = 1,500 Da, 5.2 x 10
-2
 mmol) instead of 3,6-dixoa-1,8-octanedithiol.  
 
Synthesis of polycarbonate/polyglycidol hydrogel via thiolene click (PC-PG and PC-1.5k-
PG) 
 
3,6-dixoa-1,8-octanedithiol (8.6 uL, 5.2 x 10
-2
 mmol) was added to a solution of poly(MAC, 
MEC) (100 mg, Mn = 4,712 Da, 0.105 mmol alkene), polyglycidol (100 mg), and 2,2-
dimethoxy-2-phenylacetophenone (DMPA, 0.2 eq per alkene, 5.4 mg) in DMF (100 uL). The 
solution was UV-irradiated (365 nm) for 5 minutes. The resulting gel (PC-PG) was soaked and 
rinsed sequentially with methanol and water to remove unreacted starting material and solvent, 
and gel was dried via lyophilization. Gels containing longer crosslinker (PC-1.5k-PG) were 
synthesized in the same manner but using PEG-dithiol (78.6 mg, Mn = 1,500 Da, 5.2 x 10
-2
 
mmol) instead of 3,6-dixoa-1,8-octanedithiol. 
 
Synthesis of PTX-loaded hydrogels and encapsulation efficiency 
Hydrogels were synthesized as previously described, but paclitaxel was added (10 mg paclitaxel 
per 100 mg poly(MAC, MEC)) to the polymer solution prior to UV irradiation. The resulting 
gels were soaked and rinsed with water multiple times. The washes were collected, lyophilized, 
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and analyzed by HPLC to determine mass of non-encapsulated paclitaxel. Encapsulation 
efficiency was determined using the equation: 
(
    ( )      ( )
    ( )
)        
where Mptx(i) is the initial mass of paclitaxel added to the reaction and Mptx(w) is the mass of 
washed paclitaxel determined by HPLC. 
 
Swelling studies 
Prepared gels were soaked in deionized water or simulated gastric fluid (pH = 1.2) and allowed 
to swell for 24 hours. The swelled gels were then gently blotted dry before recording the swelled 
mass (Msw), and the sample was then lyophilized to record the dry mass (Mdry). The percent 
water content post-swelling was quantified using the following equation: 
(        )
    
      
 
In vitro drug release 
The release of paclitaxel from the gels was measured in PBS (pH 7.4) or simulated gastric fluid 
(pH 1.2), both buffers containing Tween-80 (0.1% v/v) and stirred at 37 °C. Initial paclitaxel 
concentration was 0.15 mM. At each time point, the supernatant was collected and replaced with 
an equal volume of fresh release medium. For release studies in PBS, the supernatant was 
directly analyzed by HPLC. For release studies in simulated gastric fluid, the supernatant was 
neutralized to pH 7 with sodium bicarbonate, extracted three times with dichloromethane, 
organic fractions were combined, and solvent was evaporated. The resulting sample was 
dissolved in acetonitrile/water (1:1, v/v) and analyzed by HPLC. Samples were injected (30 uL) 
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to a reverse phase column (100 x 4.6 mm i.d., pore size 5 um, Thermo Scientific) using an 
isocratic gradient of acetonitrile and water (1:1, v/v) with a variable wavelength detector (227 
nm). 
 
Degradation Studies 
An initial swelled mass (Mi) was recorded by submerging the gels in PBS (pH 7.4) for 24 hours 
and gently blotting dry before recording the mass. Gels were then submerged in PBS (pH 7.4) at 
37 °C for the duration of the experiment. At each time point, the gels were gently blotted and a 
mass was recorded (Mt) before being submerged into fresh PBS (pH 7.4) at 37 °C. The percent 
mass remaining at each time point was quantified using the following equation: 
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